

COMMON PEDIATRIC DISEASES: AN UPDATED REVIEW



Editors:
Nima Rezaei
Noosha Samieefar

Bentham Books

Updates on Pediatric Health and Diseases

(Volume 1)

Common Pediatric Diseases: an Updated Review

Edited by

Nima Rezaei

&

Noosha Samieefar

*Network of Interdisciplinarity
in Neonates and Infants (NINI),
Universal Scientific Education
and Research Network (USERN),
Tehran, Iran*

Updates on Pediatric Health and Diseases

Common Pediatric Diseases: an Updated Review

Volume # 1

Editors: Nima Rezaei & Noosha Samieefar

ISBN (Online): 978-981-5039-65-8

ISBN (Print): 978-981-5039-66-5

ISBN (Paperback): 978-981-5039-67-2

©2022, Bentham Books imprint.

Published by Bentham Science Publishers Pte. Ltd. Singapore. All Rights Reserved.

BENTHAM SCIENCE PUBLISHERS LTD.

End User License Agreement (for non-institutional, personal use)

This is an agreement between you and Bentham Science Publishers Ltd. Please read this License Agreement carefully before using the ebook/echapter/ejournal (“**Work**”). Your use of the Work constitutes your agreement to the terms and conditions set forth in this License Agreement. If you do not agree to these terms and conditions then you should not use the Work.

Bentham Science Publishers agrees to grant you a non-exclusive, non-transferable limited license to use the Work subject to and in accordance with the following terms and conditions. This License Agreement is for non-library, personal use only. For a library / institutional / multi user license in respect of the Work, please contact: permission@benthamscience.net.

Usage Rules:

1. All rights reserved: The Work is the subject of copyright and Bentham Science Publishers either owns the Work (and the copyright in it) or is licensed to distribute the Work. You shall not copy, reproduce, modify, remove, delete, augment, add to, publish, transmit, sell, resell, create derivative works from, or in any way exploit the Work or make the Work available for others to do any of the same, in any form or by any means, in whole or in part, in each case without the prior written permission of Bentham Science Publishers, unless stated otherwise in this License Agreement.
2. You may download a copy of the Work on one occasion to one personal computer (including tablet, laptop, desktop, or other such devices). You may make one back-up copy of the Work to avoid losing it.
3. The unauthorised use or distribution of copyrighted or other proprietary content is illegal and could subject you to liability for substantial money damages. You will be liable for any damage resulting from your misuse of the Work or any violation of this License Agreement, including any infringement by you of copyrights or proprietary rights.

Disclaimer:

Bentham Science Publishers does not guarantee that the information in the Work is error-free, or warrant that it will meet your requirements or that access to the Work will be uninterrupted or error-free. The Work is provided "as is" without warranty of any kind, either express or implied or statutory, including, without limitation, implied warranties of merchantability and fitness for a particular purpose. The entire risk as to the results and performance of the Work is assumed by you. No responsibility is assumed by Bentham Science Publishers, its staff, editors and/or authors for any injury and/or damage to persons or property as a matter of products liability, negligence or otherwise, or from any use or operation of any methods, products instruction, advertisements or ideas contained in the Work.

Limitation of Liability:

In no event will Bentham Science Publishers, its staff, editors and/or authors, be liable for any damages, including, without limitation, special, incidental and/or consequential damages and/or damages for lost data and/or profits arising out of (whether directly or indirectly) the use or inability to use the Work. The entire liability of Bentham Science Publishers shall be limited to the amount actually paid by you for the Work.

General:

1. Any dispute or claim arising out of or in connection with this License Agreement or the Work (including non-contractual disputes or claims) will be governed by and construed in accordance with the laws of Singapore. Each party agrees that the courts of the state of Singapore shall have exclusive jurisdiction to settle any dispute or claim arising out of or in connection with this License Agreement or the Work (including non-contractual disputes or claims).
2. Your rights under this License Agreement will automatically terminate without notice and without the

need for a court order if at any point you breach any terms of this License Agreement. In no event will any delay or failure by Bentham Science Publishers in enforcing your compliance with this License Agreement constitute a waiver of any of its rights.

3. You acknowledge that you have read this License Agreement, and agree to be bound by its terms and conditions. To the extent that any other terms and conditions presented on any website of Bentham Science Publishers conflict with, or are inconsistent with, the terms and conditions set out in this License Agreement, you acknowledge that the terms and conditions set out in this License Agreement shall prevail.

Bentham Science Publishers Pte. Ltd.

80 Robinson Road #02-00

Singapore 068898

Singapore

Email: subscriptions@benthamscience.net



CONTENTS

PREFACE	i
ACKNOWLEDGEMENT	iii
DEDICATION	iv
LIST OF CONTRIBUTORS	v
CHAPTER 1 INTRODUCTION OF COMMON PEDIATRIC DISEASES	1
<i>Nima Rezaei and Noosha Samieefar</i>	
INTRODUCTION	1
EPIDEMIOLOGY	2
PEDIATRIC DISEASES TREND	3
INTEGUMENTARY SYSTEM	4
Impetigo	4
Folliculitis	4
Furuncle (Boil)	4
Staphylococcal Scalded Skin Syndrome (SSSS)	4
Molluscum Contagiosum	4
Rubella	5
Measles	5
Herpes Simplex	5
Varicella	5
Hand-Foot-Mouth Syndrome	5
Fifth Disease	5
Sixth Disease	5
Tinea Capitis	6
Tinea Versicolor	6
Scabies	6
Pediculosis	6
Sclerema Neonatorum	6
Acne Vulgaris	6
Psoriasis	6
Dermatitis	6
Pityriasis Rosea	7
Erythema Toxicum Neonatorum	7
Erythema Multiforme	7
Vitiligo	7
Pityriasis Alba	7
Dermal Melanosis	7
Pyogenic Granuloma	7
Port-Wine Stain	7
Infantile Hemangioma	8
Nevus Simplex	8
Intertrigo	8
Milia	8
Alopecia Areata	8
RESPIRATORY SYSTEM	8
Choanal Stenosis (Atresia)	8
Adenoid Hypertrophy	8
Laryngomalacia	9

Rhinosinusitis	9
Epiglottitis	9
Croup	9
Bronchiolitis	9
Pneumonia	9
Influenza	9
Asthma	10
Acute Respiratory Distress Syndrome (ARDS)	10
Transient Tachypnea of the Newborn (TTN)	10
Bronchopulmonary Dysplasia (BPD)	10
Meconium Aspiration Syndrome	10
Cystic Fibrosis	10
Pneumothorax and Pneumomediastinum	10
Pleural Effusion	10
Pulmonary Edema	11
Cor Pulmonale	11
CARDIAC SYSTEM	11
Syncope	11
Arrhythmias	11
Heart Failure	11
Rheumatic Fever	11
Cardiomyopathies (CM)	11
Pericarditis	12
Atrial Septal Defect (ASD)	12
Endocardial Cushion Defect (ECD)	12
Patent Ductus Arteriosus (PDA)	12
Ventricular Septal Defect (VSD)	12
Tricuspid Atresia	12
Pulmonary or Aortic Stenosis	12
Coarctation of the Aorta (COA)	12
Tetralogy of Fallot	12
CIRCULATORY SYSTEM	13
Anemia	13
Hemostatic Diseases	13
Immune Thrombocytopenia (ITP)	13
Vasculitis	13
Leukemia	13
Lymphoma	13
DIGESTIVE SYSTEM	13
Cleft Lip and Palate	14
Esophageal Atresia (EA) with or without tracheoesophageal fistula (TEF)	14
Esophageal Reflux	14
Peptic Ulcer Disease	14
Gastrointestinal Bleeding (GIB)	14
Pyloric Stenosis	14
Intestinal Atresia	14
Intestinal Obstruction (IO)	14
Malrotation	15
Meckel Diverticulum	15
Infantile Colic	15
Gastroenteritis	15

Irritable Bowel Syndrome (IBS)	15
Inflammatory Bowel Disease (IBD)	15
Intussusception	15
Celiac Disease	16
Lactose Intolerance	16
Hirschsprung Disease (HSCR)	16
Constipation	16
Encopresis	16
Imperforate Anus	16
Gastroschisis	16
Omphalocele	16
Cholestasis	17
Hepatitis	17
Wilson Disease	17
Pancreatitis	17
Peritonitis	17
Appendicitis	17
ENDOCRINE SYSTEM	17
Pubertal Delay	17
Precocious Puberty	18
Diabetes Mellitus (DM)	18
Hypothyroidism	18
Autoimmune Thyroiditis (AIT)	18
Hyperthyroidism	18
Primary Adrenal Insufficiency (PAI)	19
Cushing Syndrome	19
Metabolic Disorders	19
SKELETAL SYSTEM	19
Osteomyelitis (OM)	19
Septic Arthritis	19
Juvenile Idiopathic Arthritis (JIA)	19
Scaphoid Fracture	20
Nurse Maid's Elbow	20
Glenohumeral Dislocation	20
Little Leaguer's Shoulder	20
Metatarsus Adductus	20
Hypermobile Planus	20
Cavus Foot	20
Talipes Equivarus (TEV)	20
Curly Deformity	20
Sever Disease	21
Toddler's Fracture	21
Angular Variation (Genu Varum and Valgum)	21
Osteochondritis Dissecans	21
Baker Cyst	21
Osgood-Schlatter Disease (OSD)	21
Patellofemoral Pain Syndrome (PFPS)	21
Developmental Dislocation of the Hip (DDH)	21
Leg-Length Discrepancy (LLD)	21
Torsional Variation (In-toeing and Out-toeing)	22
Legg-Calve-Perthes Disease (LCPD)	22

Slipped Capital Femoral Epiphysis (SCFE)	22
Transient Synovitis	22
Scoliosis	22
Kyphosis	22
Torticollis	22
Diskitis	22
Salter Harris Fracture	22
Osteoid Osteoma	22
Osteochondroma	23
Sarcoma	23
NERVOUS SYSTEM	23
Stroke	23
Seizures	23
Tension Headache	23
Migraine	23
Meningitis	23
Encephalitis	23
Transverse Myelitis	24
Spinal Muscular Atrophy (SMA)	24
Guillain-Barre Syndrome	24
Myasthenia Gravis	24
Duchenne Muscular Dystrophy	24
Pseudotumor Cerebri	24
Spina Bifida	24
Holoprosencephaly (HPE)	24
Hydrocephalus	24
Neuroblastoma (NB)	24
GENTOURINARY SYSTEM	25
Hypertension	25
Acute Renal Failure (AKI)	25
Chronic Renal Failure	25
Nephrotic Syndrome	25
Glomerulonephritis (GN)	25
Hemolytic Uremic Syndrome (HUS)	25
Vesicoureteral Reflux (VUR)	25
Nephrolithiasis	26
Wilms Tumor	26
Undescended Testes (UDT)	26
Testicular Torsion	26
Epididymitis	26
Posterior Urethral Valve (PUV)	26
Chordee	26
Paraphimosis	26
Phimosis	26
Hypospadias	27
Labial Fusion	27
Vulvovaginitis	27
Lichen Sclerosus	27
IMMUNE SYSTEM	27
Autoimmune Disorders	27
Allergies	27

Immunodeficiencies	28
CONCLUSION	28
CONSENT FOR PUBLICATION	28
CONFLICT OF INTEREST	28
ACKNOWLEDGEMENT	28
REFERENCES	28

CHAPTER 2 UPDATES ON PEDIATRIC RHEUMATOLOGIC DISEASES 40

Anju Gupta

RHEUMATOLOGICAL DISEASES IN CHILDREN	40
When to Suspect Rheumatologic Disorders	41
<i>Approach to a Child with Joint Pains</i>	41
<i>Whether the Pain is Articular or Not?</i>	41
<i>Is the Pain Inflammatory or Non-inflammatory?</i>	42
<i>Is the Involvement Acute or Chronic?</i>	43
<i>Pattern of Joint Involvement</i>	44
<i>Extra-articular Involvement</i>	44
<i>What is Arthritis</i>	44
<i>Conditions Mimicking Chronic Arthritis</i>	45
<i>Approach to a Child with a Multisystem Disorder</i>	45
<i>Approach to a Child with Suspected Vasculitis</i>	46
Investigations in Rheumatology	47
<i>Hemogram</i>	47
<i>Liver Function Test</i>	47
<i>Coagulogram</i>	48
<i>C-reactive Protein (CRP)</i>	48
<i>Renal Function Tests</i>	48
<i>Lipid Profile</i>	48
<i>Serum Ferritin</i>	48
<i>Radiology</i>	49
<i>Complement</i>	50
<i>Autoantibodies</i>	50
<i>Tissue Diagnosis</i>	52
SPECIFIC RHEUMATOLOGICAL CONDITIONS	52
JUVENILE IDIOPATHIC ARTHRITIS	52
ILAR Classification	53
<i>Oligoarthritis</i>	53
<i>Polyarthritis</i>	54
<i>Enthesitis Related Arthritis (ERA)</i>	55
<i>Juvenile Psoriatic Arthritis</i>	56
<i>Undifferentiated Arthritis</i>	57
<i>Systemic JIA</i>	57
<i>sJIA with Active Systemic Features (and Without Active Arthritis)</i>	59
<i>sJIA with Active Arthritis (without Active Systemic Features)</i>	60
SYSTEMIC LUPUS ERYTHEMATOUS (SLE)	61
Clinical Features	61
Genetic Forms of SLE	64
Investigations	64
Diagnosis	65
Treatment	65
Monitoring	66

Outcome	67
Conclusion	67
Neonatal Lupus	67
JUVENILE SCLERODERMA	68
Juvenile Localized Scleroderma (JLS)	68
<i>Linear Scleroderma</i>	69
<i>Circumscribed Morphea</i>	70
<i>Generalized Morphea</i>	70
<i>Pansclerotic Morphea</i>	70
Mixed Subtype	71
<i>Extracutaneous Manifestations</i>	71
<i>Investigations</i>	71
<i>Treatment</i>	71
<i>Outcome</i>	72
Juvenile Systemic Sclerosis (JSSc)	72
<i>Clinical Features</i>	72
<i>Diagnosis</i>	74
<i>Investigations</i>	76
<i>Treatment</i>	76
<i>Outcome</i>	76
JUVENILE DERMATOMYOSITIS (JDM)	77
Clinical Features	77
Investigations	81
Diagnosis	82
Complications	82
Treatment	84
Monitoring	85
Outcome	85
VASCULITIS IN CHILDREN	85
IgA Vasculitis (IgAV)	87
<i>Pathophysiology</i>	87
<i>Clinical Features</i>	87
<i>Investigations</i>	90
<i>Diagnosis</i>	90
<i>Treatment</i>	90
<i>Treatment of IgAV Nephritis</i>	91
ANCA Associated Vasculitis (AAV)	92
<i>Epidemiology</i>	92
<i>Clinical Features</i>	92
<i>Diagnosis</i>	94
<i>Treatment</i>	94
<i>Outcome</i>	95
Kawasaki Disease	95
<i>Epidemiology</i>	95
<i>Etiology</i>	95
<i>Pathogenesis</i>	96
<i>Clinical Features</i>	96
<i>Investigations</i>	101
<i>Diagnosis</i>	102
<i>Incomplete KD</i>	103
<i>Differential Diagnosis</i>	103

<i>Treatment</i>	104
<i>IVIg Resistance</i>	105
<i>Long-term Management</i>	105
<i>Conclusion</i>	106
Polyarteritis Nodosa	106
<i>Clinical Features</i>	107
<i>Investigations</i>	107
<i>Treatment</i>	107
Takayasu Arteritis	108
<i>Epidemiology</i>	108
<i>Pathology</i>	108
<i>Clinical Features</i>	108
<i>Types</i>	109
<i>Diagnosis</i>	110
<i>Differential Diagnosis</i>	112
<i>Treatment</i>	112
<i>Monitoring</i>	114
<i>Outcome</i>	114
ANTIPHOSPHOLIPID SYNDROME (APS)	114
Pathogenesis	115
Clinical Features	116
CATASTROPHIC APS (CAPS)	118
Diagnosis	118
Treatment	119
Treatment of Clinical Manifestations	119
Prevention of Thrombotic Manifestations	119
<i>Secondary Prevention</i>	119
<i>Primary Prevention</i>	120
Conclusion	120
UVEITIS	120
Clinical Features	121
Role of Ophthalmologist	121
Role of Pediatrician	122
Investigations	123
Treatment	123
Monitoring	124
Outcome	124
Conclusion	125
RHEUMATOLOGICAL EMERGENCIES	125
MACROPHAGE ACTIVATION SYNDROME (MAS)	125
Clinical Features	126
Investigations	127
Diagnosis	127
Treatment	128
Conclusion	129
NOTES	129
CONSENT FOR PUBLICATION	131
CONFLICT OF INTEREST	131
ACKNOWLEDGEMENTS	131
REFERENCES	131

CHAPTER 3 UPDATES ON COMMON ORAL DISEASES IN CHILDREN	138
<i>Heliya Ziaei, Shahrzad Banan and Donya Alinejhad</i>	
INTRODUCTION	138
DENTAL CARIES	139
PERIODONTITIS AND GINGIVITIS	141
MALOCCLUSION	143
Oral Habits	144
Finger (Thumb) Sucking	145
Lip Biting (Sucking)	145
Nail-biting (Onychophagia)	145
Pacifier Habits	145
Bruxism	146
Tongue Thrusting	146
Mouth Breathing	146
TRAUMA	147
ORAL SOFT TISSUE LESIONS	149
Eruption Hematoma and Cyst	149
Erythema Migrans (Benign Migratory Glossitis or Geographic Tongue)	149
Aphthous Ulcer (Recurrent Aphthous Stomatitis)	150
Traumatic Lesions	150
<i>Morsicatio Buccarum</i>	150
Burns	150
TONGUE	151
Ankyloglossia	151
Geographic Tongue	151
Fissured Tongue	152
Coated Tongue (Hairy Tongue)	152
Bifid Tongue	153
INFECTIONS	153
Primary Herpetic Gingivostomatitis	153
Oropharyngeal Candidiasis	153
Secondary Herpetic Ulcer	154
Angular Cheilitis	154
Hand-Foot-Mouth Disease	154
Periapical Primary Teeth Lesions	155
<i>Periapical Abscess</i>	155
<i>Cellulitis</i>	155
CONGENITAL DISEASES	156
Abnormal Tooth Development	156
<i>Hyperdontia</i>	156
<i>Hypodontia</i>	157
<i>Taurodontism</i>	158
<i>Dens Invaginatus</i>	158
<i>Dens Evaginatus</i>	158
<i>Amelogenesis Imperfecta</i>	158
HEMANGIOMA AND LYMPHANGIOMA	159
GINGIVAL	160
Cyst of Newborn	160
<i>Epstein Pearls</i>	160
<i>Bohn Nodule</i>	160

<i>Gingival Cyst of the Newborn (Dental Lamina Cyst)</i>	160
CONCLUSION	160
CONSENT FOR PUBLICATION	161
CONFLICT OF INTEREST	161
ACKNOWLEDGEMENT	161
REFERENCES	161
CHAPTER 4 UPDATES ON PEDIATRIC METABOLIC SYNDROME	171
<i>Caroline Brand, Cézane P. Reuter and Roya Kelishadi</i>	
INTRODUCTION	172
DEFINITION AND PREVALENCE	172
RISK FACTORS FOR METS: THE CENTRAL ROLE OF OBESITY	174
THE INFLUENCE OF LIFESTYLE AND EARLY RISK FACTORS	176
MANAGEMENT OF PEDIATRIC METS	178
CONCLUSION	180
CONSENT FOR PUBLICATION	180
CONFLICT OF INTEREST	180
ACKNOWLEDGEMENT	180
REFERENCES	181
CHAPTER 5 UPDATES ON PEDIATRIC EPILEPSY SYNDROMES	186
<i>Ahmed Nugud, Alaa Nugud, Assmaa Nugud and Shomous Nugud</i>	
INTRODUCTION	186
DIAGNOSTIC PROCEDURES	192
Lumbar Puncture	192
Electroencephalogram	192
Radiological Investigations	193
PEDIATRIC EPILEPSY	195
Febrile Seizures	195
Febrile Infection-related/refractory Epilepsy	196
Dravet Syndrome	196
Focal Seizures	197
Benign Epilepsy Syndromes with Focal Seizures	197
Severe Epilepsy Syndromes with Focal Seizures	198
Generalized Motor Seizures	198
Benign Generalized Epilepsies	201
Severe Generalized Epilepsies	202
West Syndrome	202
Lennox-Gastaut Syndrome	203
Landau-Kleffner Syndrome	204
METABOLIC EPILEPSY SYNDROMES	204
Metabolic Epilepsy Related to Insulin/energy Regulation Disorders	205
APPROACHES TO EPILEPSY SURGERY	205
Neurodevelopmental and Behavioral Health Evaluation	206
Surgical Outcomes	206
CONCLUSION	207
LIST OF ABBREVIATIONS	207
CONSENT FOR PUBLICATION	208
CONFLICT OF INTEREST	208
ACKNOWLEDGEMENT	208
REFERENCES	208

CHAPTER 6 UPDATES ON PEDIATRIC GENETIC EPILEPTIC ENCEPHALOPATHIES: A DIAGNOSTIC ALGORITHMIC APPROACH	210
<i>Vikas Dhiman, Shwetha Chiplunkar and Rajnarayan R Tiwari</i>	
INTRODUCTION	211
NEONATAL EPILEPTIC ENCEPHALOPATHIES	211
Ohtahara Syndrome	212
Early Myoclonic Encephalopathy (EME)	213
INFANTILE EPILEPTIC ENCEPHALOPATHIES	213
Benign Familial Infantile Seizures (BFIS)	213
Generalized Epilepsy with Febrile Seizures Plus (GEFS+)	214
Dravet Syndrome	214
West Syndrome	214
Myoclonic Encephalopathy in Non-progressive Disorders	215
Epilepsy of Infancy with Migrating Focal Seizures	215
EPILEPTIC ENCEPHALOPATHIES OF CHILDHOOD AND ADOLESCENCE	216
Benign Childhood Epilepsy with Centrottemporal Spikes (BCECTS)	216
Early-onset Childhood Occipital Epilepsy (Panayiotopoulos Type)	217
Late-onset Childhood Occipital Epilepsy (Gastaut Syndrome)	217
Epilepsy with Myoclonic Atonic (Astatic) Seizures (Doose Syndrome)	218
Lennox-Gastaut Syndrome	218
Landau-Kleffner Syndrome	219
Continuous Spike-wave During Sleep (CSWS)	220
EPILEPTIC ENCEPHALOPATHIES OF VARIABLE AGE	220
Progressive Myoclonic Epilepsies	220
DIAGNOSTIC ALGORITHMS	223
CONCLUSION	225
CONSENT FOR PUBLICATION	226
CONFLICT OF INTEREST	226
ACKNOWLEDGEMENT	226
REFERENCES	226
CHAPTER 7 UPDATES ON PEDIATRIC DEMYELINATING DISORDERS	231
<i>Amit Agrawal and Umesh Pandwar</i>	
INTRODUCTION	232
CLASSIFICATION OF PEDIATRIC DEMYELINATING DISEASES	233
Acute Disseminated Encephalomyelitis	233
<i>Epidemiology</i>	233
<i>Pathogenesis</i>	234
<i>Clinical Manifestations</i>	234
<i>Neuroimaging</i>	234
<i>Laboratory Findings</i>	235
<i>Differential Diagnosis</i>	235
<i>Treatment</i>	236
<i>Prognosis</i>	236
Multiple Sclerosis	236
<i>Epidemiology</i>	236
<i>Risk Factors</i>	237
<i>Pathogenesis</i>	237
<i>Clinical Manifestations</i>	237
<i>Neuroimaging</i>	238
<i>Laboratory Findings</i>	238

<i>Diagnosis</i>	238
<i>Differential Diagnosis</i>	239
<i>Treatment</i>	239
<i>Immunomodulatory Therapy</i>	239
<i>Second-Line Therapies</i>	239
<i>Prognosis</i>	240
Optic Neuritis	240
<i>Clinical Presentation</i>	241
<i>Diagnosis</i>	241
<i>Treatment</i>	242
<i>Prognosis</i>	242
Transverse Myelitis	242
<i>Epidemiology</i>	243
<i>Clinical Manifestations</i>	243
<i>Diagnostic Evaluation and Differential Diagnosis</i>	244
<i>Treatment</i>	245
Neuromyelitis Optica Spectrum Disorders	245
<i>Epidemiology</i>	245
<i>Pathogenesis</i>	246
<i>Clinical Manifestations</i>	246
<i>Imaging</i>	246
<i>Laboratory Findings</i>	247
<i>Diagnosis</i>	247
<i>Differential Diagnosis</i>	247
<i>Treatment</i>	248
<i>Prognosis</i>	248
Schilder's Disease	248
<i>Epidemiology</i>	248
<i>Clinical Presentation</i>	249
<i>Diagnosis</i>	249
<i>Treatment</i>	249
CONCLUSION	252
CONSENT FOR PUBLICATION	252
CONFLICT OF INTEREST	252
ACKNOWLEDGEMENT	252
REFERENCES	252
CHAPTER 8 UPDATES ON ATOPIC DERMATITIS	260
<i>Edna Morán-Villaseñor and María Teresa García-Romero</i>	
INTRODUCTION	260
EPIDEMIOLOGY	261
ETIOLOGY	261
IMPAIRED SKIN BARRIER FUNCTION	261
Decreased Filaggrin	262
Decreased Ceramides	262
Decreased Production of Antimicrobial Peptides	263
Decreased Serine Protease Inhibitors and Increased Serine Protease	263
Tight Junction Disorder	263
Immune Dysfunction	263
Increased Thymic Stromal Lymphopoietin	264
Increased Production of Th2 and Th22 Cytokines	264

Altered Skin Microbiota	265
Genetic Factors	266
Family History	266
Genetic Mutations	266
Race/ethnicity	266
Environmental Factors	267
Climate	267
Pet Ownership	267
Rural vs Urban Living	267
Diet	268
CLINICAL COURSE	268
Age Related Distribution	269
Infantile	269
Childhood	269
Adult	269
Morphological Variants	270
Follicular Type	270
Papular-lichenoid	270
Prurigo-like	270
Nummular Pattern	270
Erythroderma	271
Associated Clinical Features	271
COMORBIDITIES	272
Association with Allergic Disease	272
Contact Sensitizations	273
Depression, Anxiety and Attention Deficit Hyperactivity Disorder	273
Sleep Disturbances	273
COMPLICATIONS	274
Infections	274
<i>Bacterial</i>	274
<i>Viral</i>	275
<i>Eczema Herpeticum</i>	275
<i>Eczema Coxsackium</i>	275
<i>Eczema Molluscatum</i>	275
Quality of Life	275
<i>Assessment of Quality of Life</i>	276
DIAGNOSIS	276
Diagnostic Criteria	276
Laboratories	279
Skin Biopsy	280
DISEASE SEVERITY	280
DIFFERENTIAL DIAGNOSIS	282
MANAGEMENT	283
Maintenance Skin Care	283
<i>Moisturizers</i>	284
<i>Bathing</i>	285
<i>Trigger Avoidance</i>	285
Others	285
<i>Bleach Baths</i>	285
<i>Wet-wrap Therapy</i>	286
<i>Itch Control</i>	286

Anti-inflammatory Agents	287
<i>Topical Therapies</i>	287
Systemic Therapies	288
<i>Phototherapy</i>	288
Systemic Immunomodulatory Agents	289
<i>Cyclosporine A</i>	289
<i>Methotrexate</i>	289
<i>Azathioprine</i>	289
<i>Mycophenolate Mofetil</i>	290
<i>Systemic Corticosteroids</i>	290
<i>Anti-IL-4 (Dupilumab)</i>	290
<i>New Therapies</i>	291
Other Treatments	293
<i>Oral Supplementation</i>	293
Therapeutic Patient Education	294
PREVENTION	294
Emollient Use	294
Breastfeeding	295
Probiotic Supplementation	295
PROGNOSIS	296
CONCLUSION	296
CONSENT FOR PUBLICATION	296
CONFLICT OF INTEREST	297
ACKNOWLEDGEMENT	297
REFERENCES	297
CHAPTER 9 UPDATES ON HENOCH-SCHONLEIN PURPURA	310
<i>Patricia Morán-Álvarez, Guillermo Santos-Simarro and Fernando Santos</i>	
INTRODUCTION	311
EPIDEMIOLOGY	311
PATHOGENESIS	312
CLINICAL FEATURES	313
Purpura	313
Articular Manifestations	315
Gastrointestinal Manifestations	315
Nephropathy	315
Other Manifestations	316
DIFFERENTIAL DIAGNOSIS	316
TREATMENT	317
Treatment of Skin Involvement	317
Treatment of Musculoskeletal Involvement	317
Treatment of Gastrointestinal Involvement	318
Treatment of Renal Involvement	318
Miscellaneous Treatments	319
PROGNOSIS	319
CONCLUSION	320
CONSENT FOR PUBLICATION	321
CONFLICT OF INTEREST	321
ACKNOWLEDGEMENT	321
REFERENCES	321

CHAPTER 10 UPDATES ON CHILDHOOD-ONSET SYSTEMIC LUPUS	
ERYTHEMATOSUS	324
<i>Selma Cecilia Scheffler Mendoza, Francisco Eduardo Rivas-Larrauri and Ana Luisa Rodríguez-Lozano</i>	
INTRODUCTION	325
EPIDEMIOLOGY	325
GENETIC AND PATHOGENESIS	326
Monogenic Lupus	327
Complement Deficiency	329
Abnormal DNA Clearance and Interferonopathies	330
Prolidase Deficiency	331
Protein Kinase-Cδ Deficiency	331
RASopathies	331
CLASSIFICATION AND DIAGNOSIS	332
CLINICAL MANIFESTATIONS	336
1. Lupus Erythematosus Specific Skin Lesions	337
2. Lupus Erythematosus Nonspecific Skin Lesions	338
DISEASE ACTIVITY AND DAMAGE ACCRUAL	342
TREATMENT	351
Conventional Immunomodulation	352
<i>Glucocorticoids (GC)</i>	352
<i>Hydroxychloroquine</i>	353
<i>Disease-Modifying Anti-Rheumatic Drugs (DMARD)</i>	353
<i>Azathioprine (AZA)</i>	353
<i>Mycophenolate Mofetil (MMF)</i>	354
<i>Cyclophosphamide (CYC)</i>	354
Targeted Immunotherapy	355
B-Cell	355
<i>T-Cells</i>	356
<i>Interferons (IFN)</i>	357
<i>Cytokines</i>	357
a. Tocilizumab (TCZ)	357
b. Anti-TNF	358
c. Janus Kinase/Signal Transducer and Activator of Transcription Inhibition.	358
<i>Complement</i>	358
Transplant	358
Other Treatment Recommendations	359
Others	359
<i>Intravenous Immunoglobulin G (IVIg)</i>	359
OUTCOME	360
CONCLUSION	361
CONSENT FOR PUBLICATION	362
CONFLICT OF INTEREST	362
ACKNOWLEDGEMENT	362
REFERENCES	362
CHAPTER 11 UPDATES ON SEVERE COMBINED IMMUNODEFICIENCY	375
<i>Fausto Cossu</i>	
INTRODUCTION	375
NO NEWBORN SCREENING FOR SCID	376
1) Atypical SCID by Leaky Mutations	379

2) SCID with Massive Engraftment of Transplacentally Derived Maternal T Lymphocytes	379
3) Omenn Syndrome (OS)	380
GENETICS	382
SCID Caused by Cytokine Signaling Defects	383
<i>Common Gamma Chain (γc) Deficiency ("SCIDX-1")</i>	383
<i>Janus Associated Kinase-3 (JAK3) Deficiency</i>	385
<i>Interleukin-7 Receptor α Chain (IL7Rα) Deficiency</i>	385
SCID Caused by Pre-T Cell Receptor Defects	385
1) Defects of V(D)J Recombination	386
RAG1/RAG2 Deficiencies	387
NHEJ Deficiencies (Defects in DNA Repair Genes)	388
<i>Artemis Deficiency (ART-SCID)</i>	389
<i>DNA-PKcs Deficiency</i>	389
<i>DNA ligase IV Deficiency</i>	390
<i>Cernunnos (XLF) Deficiency</i>	390
2) Impaired Signaling through the Pre-T cell Receptor	390
<i>(Defects of the CD3-TCR Complex and of its Signaling Pathway)</i>	390
SCID Caused by Metabolic Disorders	392
<i>Reticular Dysgenesis (RD)</i>	392
<i>Adenosine Deaminase-1 Deficiency (ADA-SCID)</i>	393
Other SCIDs	395
<i>Coronin 1A Deficiency</i>	395
Other "Non-Classical" SCIDs	395
Purine Nucleoside Phosphorylase (PNP) Deficiency	397
ORAI1 Deficiency - STIM1 Deficiency (Impaired Calcium Flux)	397
MHC II Deficiency	398
Cartilage-hair Hypoplasia (CHH)	399
Thymic Disorders (Defect in Thymus Embryogenesis, "Athymia")	399
Examples of SCID Cohorts	401
NEWBORN SCREENING FOR SCID	402
"Idiopathic" T Cell Lymphopenia	405
DIAGNOSIS	405
TREATMENT	408
Hematopoietic Stem Cell Transplantation (HSCT)	409
Autologous Hematopoietic Stem Cell Gene Therapy (HSC-GT)	411
CONCLUSION	414
PATIENT CONSENT	414
CONSENT FOR PUBLICATION	414
CONFLICT OF INTEREST	414
ACKNOWLEDGEMENTS	414
REFERENCES	415

CHAPTER 12 UPDATES ON PFAPA- PERIODIC FEVER, APHTHOUS STOMATITIS, PHARYNGITIS, AND CERVICAL ADENITIS SYNDROME	428
<i>Beata Wolska-Kuśnierz and Bożena Mikołuc</i>	
INTRODUCTION	428
ETIOLOGY	429
CLINICAL MANIFESTATIONS	430
DIAGNOSIS	431
TREATMENT	432
PROGNOSIS	433

CONCLUSION	433
CONSENT FOR PUBLICATION	434
CONFLICT OF INTEREST	434
ACKNOWLEDGEMENT	434
REFERENCES	434
CHAPTER 13 UPDATES ON PEDIATRIC HEPATOBLASTOMA	437
<i>Consolato M. Sergi</i>	
INTRODUCTION	437
TUMOR CELL OF ORIGIN	438
CLINICAL PRESENTATION	439
PATHOLOGY	439
OUTCOME AND THERAPY	444
CONCLUSION	446
CONSENT FOR PUBLICATION	447
CONFLICT OF INTEREST	447
ACKNOWLEDGMENTS	447
REFERENCES	447
CHAPTER 14 UPDATES ON MITOCHONDRIAL DISORDERS IN CHILDREN	452
<i>Ramesh Bhat Y</i>	
INTRODUCTION	453
EPIDEMIOLOGY	454
PATHOGENESIS	454
TYPES OF MITOCHONDRIAL DISORDERS	456
1. Mitochondrial Disorders Due to Defects of mtDNA	456
<i>A. Defects in Mitochondrial Protein Synthesis</i>	456
<i>B. Defects of Protein-coding Genes</i>	457
2. Leber's Hereditary Optic Neuropathy (LHON)	457
2.1. <i>Mitochondrial Disorders Due to Mutations in nDNA</i>	457
CLINICAL FEATURES	460
RECOGNISED CLINICAL SYNDROMES	461
APPROACH TO MITOCHONDRIAL DISORDERS	465
Clues from Patient History	465
LABORATORY TESTS	465
Genetic Studies	466
Neuroimaging	467
Nerve Conduction Studies and Electromyography	467
Muscle Biopsy	467
Biochemical Tests	467
TREATMENT	468
Nutrition, Ketogenic Diet, Avoiding Toxins and Exercise	470
<i>Nutrition</i>	470
<i>Ketogenic Diet</i>	471
<i>Avoiding Mitochondrial Toxins</i>	471
<i>Exercise</i>	471
Pharmacologic Treatment	472
<i>Coenzyme Q10</i>	472
<i>Riboflavin</i>	473
<i>L-Carnitine</i>	473
<i>L-Arginine</i>	473
<i>L-creatine</i>	473

<i>Redox and Other Agents</i>	474
<i>Folinic Acid</i>	474
Treatment of Epilepsy in Mitochondrial Disorder	474
Cardiomyopathy Monitoring, Cardiac Pacemakers and Defibrillators	475
Role of Organ Transplant	475
Cochlear Implants	476
Newer Therapies	476
Resveratrol	476
Gene Therapy	476
CONCLUSION	477
CONSENT FOR PUBLICATION	477
CONFLICT OF INTEREST	477
ACKNOWLEDGEMENT	477
REFERENCES	477
SUBJECT INDEX	682

PREFACE

Seeing the world through the eyes of a child/infant sounds inspirational. They are little, lovely, and defenseless. Pediatric is the science of taking care of these cute creations. Pediatric is a branch of medicine that focuses on the diagnosis and treatment of infants, children, and adolescents' diseases. As the medical sciences are getting more complex with the information explosion, interdisciplinarity is the essential tool to integrate different topics. Therefore, we established an interest group, entitled "Network of Interdisciplinarity in Neonates and Infants (NINI)" in the Universal Scientific Education and Research Network (USERN), and invited pediatricians and scientists in the field of pediatrics from all over the world to join this multidisciplinary network: <https://usern.tums.ac.ir/Group/Info/NINI>

The "Updates on Pediatric Health and Disease" series is a comprehensive text regarding childhood and adolescence health and diseases. Neonatology, as well as different diseases in all subspecialties of pediatrics, including pediatric allergy and immunology, pediatric cardiology, pediatric endocrinology, pediatric gastroenterology, pediatric hematology, pediatric infectious disease, pediatric nephrology, pediatric oncology, pediatric pulmonology, pediatric rheumatology, pediatric neurology, pediatric psychiatry, and pediatric dermatology, will be discussed in different volumes.

"Common Pediatric Diseases: An Updated Review" is the first volume of this book series; in this volume, after a rapid introduction to Pediatric diseases (Chapter 1), pediatric rheumatologic diseases are discussed (Chapter 2). Then, the book provides an update on common oral diseases (Chapter 3). Chapter 4 takes a specific view of Pediatric Metabolic Syndromes. The book also provides some chapters regarding neurologic diseases, including Pediatric Epilepsy Syndromes (Chapter 5), Pediatric Demyelinating Disorder (Chapter 7), and also a diagnostic algorithmic approach to Pediatric Genetic Epileptic Encephalopathies (Chapter 6). It contains several chapters concerning updates of Henoch-Schönlein purpura (Chapter 9), Atopic Dermatitis (Chapter 8), Childhood-Onset Systemic Lupus Erythematosus (Chapter 10), Severe Combined Immunodeficiency (Chapter 11), PFAPA- Periodic Fever, Aphthous Stomatitis, Pharyngitis, and Cervical Adenitis Syndrome (Chapter 12) and Pediatric Hepatoblastoma (Chapter 13).

Updates on Pediatric Health and Disease Book is the result of the valuable contribution of scientists and clinicians from well-known universities/institutes worldwide. I would like to hereby acknowledge the expertise of all contributors for generously devoting their time and considerable effort in preparing their respective chapters. I would also like to express my gratitude to the Bentham Science publication for providing me the opportunity to publish the book.

Finally, I hope that this timely book will be comprehensible, cogent, and of special value for researchers and clinicians who wish to extend their knowledge of Pediatrics.

Nima Rezaei

Network of Interdisciplinarity
in Neonates and Infants (NINI),
Universal Scientific Education
and Research Network (USERN),
Tehran, Iran

&

Noosha Samieefar

Network of Interdisciplinarity
in Neonates and Infants (NINI),
Universal Scientific Education
and Research Network (USERN),
Tehran, Iran

ACKNOWLEDGEMENT

I would like to express my gratitude to the Editorial Assistant of this book, Dr. Noosha Samieefar. Undoubtedly, the book would not have been completed without her contribution.

Nima Rezaei
Network of Interdisciplinarity
in Neonates and Infants (NINI),
Universal Scientific Education
and Research Network (USERN),
Tehran, Iran

DEDICATION

This book would not have been possible without the continuous encouragement by my family.

I wish to dedicate it to my daughters, Ariana and Arnika, with the hope that we learn enough from today to make a brighter future for the next generation.

List of Contributors

Ahmed Nugud	Al Jalila Children's Specialty Hospital, Dubai, UAE
Alaa Nugud	Latifa Women's and Children's Hospital, Dubai Health Authority, Dubai, UAE
Amit Agrawal	Department of Pediatrics, Gandhi Medical College & Hamidia Hospital, Bhopal, MP 462030, India
Anju Gupta	Department of Pediatrics, Postgraduate Institute of Medical Education and Research, Chandigarh, India
Assmaa Nugud	Ras Al Khaimah Medical and Health Sciences University, Ras Al Khaimah, UAE
Ana Luisa Rodríguez-Lozano	Immunology Department, Instituto Nacional de Pediatría, Mexico City, Mexico
Beata Wolska-Kuśnierz	Immunology Department, Children's Memorial Health Institute, Av. Dzieci Polskich 20 , 04-730 Warsaw, Poland
Bożena Mikoluc	Department of Pediatrics, Rheumatology, Immunology and Metabolic Bone Diseases, Medical University of Białystok, Waszyngtona 17 Str., 15-274 Białystok, Poland
Caroline Brand	Graduate Program in Health Promotion - University of Santa Cruz do Sul, Santa Cruz do Sul, Rio Grande do Sul, Brazil
Cézane P. Reuter	Graduate Program in Health Promotion - University of Santa Cruz do Sul, Santa Cruz do Sul, Rio Grande do Sul, Brazil
Consolato M. Sergi	Children's Hospital of Eastern Ontario (CHEO), University of Ottawa 401 Smyth Road Ottawa, ON, K1H8L1 Canada
Donya Alinejad	Department of Pediatric Dentistry, School of Dentistry, Tehran University of Medical Sciences, Tehran, Iran
Edna Morán-Villaseñor	Department of Dermatology, National Institute of Pediatrics, Mexico City 04530, Mexico
Fausto Cossu	Pediatric Clinic of University, "Antonio Cao" Hospital, Cagliari, Sardinia, Italy
Fernando Santos	Division of Pediatric Nephrology. Hospital Universitario Central de Asturias, Oviedo, Asturias, Spain Department of Medicine, University of Oviedo. Oviedo, Asturias, Spain
Francisco Eduardo Rivas-Larrauri	Immunology Service, Instituto Nacional de Pediatría, México City, México
Guillermo Santos-Simarro	Department of Pediatrics, Hospital Universitario La Paz, Madrid, Spain
Heliya Ziaei	Network of Immunity in Infection, Malignancy and Autoimmunity (NIIMA), Universal Scientific Education and Research Network (USERN), Tehran, Iran Maxillofacial Surgery & Implantology & Biomaterial Research foundation, Tehran, Iran

- María Teresa García-Romero** Department of Dermatology, National Institute of Pediatrics, Mexico City 04530, Mexico
- Nima Rezaei** Network of Interdisciplinarity in Neonates and Infants (NINI), Universal Scientific Education and Research Network (USERN), Tehran, Iran
Research Center for Immunodeficiencies, Pediatrics Center of Excellence, Children's Medical Center, Tehran University of Medical Sciences, Tehran, Iran
- Noosha Samieefar** Student Research Committee, School of Medicine, Shahid Beheshti University of Medical Sciences, Tehran, Iran
Network of Interdisciplinarity in Neonates and Infants (NINI), Universal Scientific Education and Research Network (USERN), Tehran, Iran
USERN Office, School of Advanced Technologies in Medicine, Shahid Beheshti University of Medical Sciences, Tehran, Iran
- Patricia Morán-Álvarez** Department of Rheumatology, Hospital Universitario Ramón y Cajal, Madrid, Spain
- Rajnarayan R. Tiwari** ICMR-National Institute for Research in Environmental Health (NIREH), Bhopal, Madhya Pradesh-462030, India
- Ramesh Bhat. Y.** Department of Paediatrics Kasturba Medical College Manipal Academy of Higher Education University Manipal, Karnataka, India
- Roya Kelishadi** Child Growth and Development Research Center, Research Institute for Primordial Prevention of Non-Communicable Disease, Isfahan University of Medical Sciences, Isfahan, Iran
- Selma Cecilia Scheffler-Mendoza** Immunology Service, Instituto Nacional de Pediatría, Mexico City, Mexico
- Shahrzad Banan** School of Dentistry, Guilan University of Medical Sciences, Rasht, Iran
- Shomous Nugud** University of Sharjah, Sharjah, UAE
- Shwetha Chiplunkar** Department of Pediatrics, Maidstone and Tunbridge Wells NHS Trust, Kent county ME16 9QQ, United Kingdom
- Umesh Pandwar** Department of Pediatrics, Gandhi Medical College & Hamidia Hospital, Bhopal, MP 462030, India
- Vikas Dhiman** Department of Environmental Health and Epidemiology, ICMR-National Institute for Research in Environmental Health (NIREH), Bhopal, Madhya Pradesh-462030, India

CHAPTER 1

Introduction of Common Pediatric Diseases

Nima Rezaei^{1,2,*} and Noosha Samieefar^{3,1,4}

¹ Network of Interdisciplinarity in Neonates and Infants (NINI), Universal Scientific Education and Research Network (USERN), Tehran, Iran

² Research Center for Immunodeficiencies, Pediatrics Center of Excellence, Children's Medical Center, Tehran University of Medical Sciences, Tehran, Iran

³ Student Research Committee, School of Medicine, Shahid Beheshti University of Medical Sciences, Tehran, Iran

⁴ USERN Office, School of Advanced Technologies in Medicine, Shahid Beheshti University of Medical Sciences, Tehran, Iran

Abstract: Pediatric health has improved over the past decades and there is a decline in deaths caused by infectious diseases. Yet, the top three causes of disease in children younger than 10 years in 2019 include neonatal disorders, lower respiratory tract infections, and diarrheal diseases. While in the adolescence age group, the major causes are road injuries, headache disorders, and self-harm. Preterm birth complications, pneumonia, and birth asphyxia are the most leading cause of death in children under five years. While in the five to nine years of age group, injuries, including road traffic injuries, drowning, burns, and falls, are the leading causes of death.

Keywords: Communicable disease, Disease, Epidemiology, Health, Infectious disease, Integrated medicine, Inter-disciplinary, Medicine, Morbidity, Mortality, Multi-disciplinary, Non-Communicable disease, Pediatrics, Pediatrician.

INTRODUCTION

Pediatrics, a branch of clinical medicine that studies the diseases and health conditions associated with infants, children, and adolescents, is not just a profession but solicitude. Children should not be considered tiny adults, and their diseases must be studied and investigated professionally and specifically.

With information explosion and new advances in medical sciences, pediatrics is going to be a set of subspecialties rather than just a specialty.

* **Corresponding author Nima Rezaei:** Research Center for Immunodeficiencies, Children's Medical Center Hospital, Dr. Qarib St, Keshavarz Blvd, Tehran 14194, Iran; Tel: +9821-6692-9234; Fax: +9821-6692-9235; E-mail: rezaei_nima@tums.ac.ir

This emphasizes the need to develop multidisciplinary and inter-disciplinary approaches and researches. Care coordination could be defined as “a patient- and family-centered, assessment-driven, team-based activity designed to meet the needs of children and youth while enhancing the caregiving capabilities of families. Care coordination addresses interrelated medical, social, developmental, behavioral, educational, and financial needs to achieve optimal health and wellness outcomes”. The results of such different disciplines coordination are efficient care coordination, cost efficiency, improvement of the team working, better communication with families, and finally better health outcomes [1].

Particularly, the mental health care of children is a neglected part of primary care settings. The integrated care models in multidisciplinary centers with psychiatric consults would result in better mental health outcomes [2].

Another condition in which integrated approaches are critical is the management of severe cases as they usually suffer from comorbidities simultaneously.

However, these integrated models demand a precise schedule and a well-designed set of collaborations. Additionally, all the medical services should not be directed in highly specialized pediatric centers that would reduce the local hospital referrals [3].

In this chapter, firstly, we review the epidemiology and trend of pediatric diseases. Then, a brief review of common pediatric diseases based on the organ involved is provided.

EPIDEMIOLOGY

The health status of children is improving over the years. The burden of diseases among children under 10 years has declined dramatically about 60 percent, during the years 1990-2019. The reason is better management of infectious diseases, mainly lower respiratory tract infections, diarrheal diseases, and meningitis. However, communicable diseases are still a leading cause of morbidity in children accounting for six of the top ten causes of burden in children. The main causes of disease burden in children younger than 10 years in 2019 include neonatal disorders, lower respiratory tract infections, diarrheal diseases, congenital birth defects, malaria, meningitis, dietary iron deficiency, protein-energy malnutrition, whooping cough, STIs (sexually transmitted infections excluding HIV), respectively.

In the 10-24 years age group, which include adolescents, the top ten causes of burden include road injuries, headache disorders, self-harm, depressive disorders,

interpersonal violence, anxiety disorders, low back pain, dietary iron deficiency, HIV/AIDS, and diarrheal diseases, respectively [4].

The common causes of death among children could be categorized as follows: 1. Respiratory diseases like pneumonia, whooping cough, *etc.* 2. Gastrointestinal diseases like diarrhea, hepatitis, *etc.* 3. Malnutrition and nutritional disorders 4. Malaria 5. Chronic neurological diseases include hydrocephalus, cerebral palsy, and so on 6. Acute neurological diseases such as meningitis, encephalitis, *etc.* 7. Tuberculosis leading to pulmonary, extra-pulmonary, or disseminated involvements 8. Acute rash and fever/infection like Measles, dengue fever, *etc.* 9. HIV infection 10. Emergencies like bowel obstruction, trauma, poisoning, *etc.* 11. Renal diseases include urinary tract infection, acute renal failure, chronic renal failure, *etc.* 12. Endocrine diseases such as diabetes and thyroid diseases 13. Hematological disorders like anemia, bleeding disorders, *etc.* 14. Heart diseases 15. Cancer 16. Child protection problems like sexual and physical abuse, neglect, homicide, suicide, and so on 17. Low birth weight 18. Prematurity 19. Neonatal infections e cord sepsis, congenital infections (examples include syphilis, malaria, rubella), *etc.* 20. Perinatal conditions such as birth asphyxia, respiratory distress syndrome, *etc.* 21. Congenital malformations like malrotations, gastroschisis, imperforate anus, *etc.* [5].

Preterm birth complications, pneumonia, birth asphyxia, diarrhea, and malaria are reported to be the top five causes of death in children under five years. While in five to nine years of age group injuries, including road traffic injuries, drowning, burns, and falls, are the leading causes of death [6].

According to the United Nations Inter-agency Group for Child Mortality Estimation (UN IGME) report, 6.2 million deaths in children younger than 15 years were recorded only in 2018. Unfortunately, most of these deaths are from preventable causes, and most are in the youngest group, neonates [7].

Although there have been improvements in declining the death rate, there is much to do. The mortality rate has declined from 76 to 39 per 1000 from 2000 to 2018. Many of these deaths occur in sub-Saharan Africa [6].

PEDIATRIC DISEASES TREND

Overall, with increasing Socio-demographic Index or SDI (an index of social development evaluation), pediatric diseases are shifting from communicable to non-communicable [4]. Now, more attention is attracted to psychological and behavioral morbidities and mental health [8].

Updates on Pediatric Rheumatologic Diseases

Anju Gupta^{1,*}

¹ Department of Pediatrics, Postgraduate Institute of Medical Education and Research, Chandigarh, India

Abstract: Rheumatological disorders pose a challenge to clinicians because of multisystemic involvement, relapsing-remitting course, and nonspecific clinical features, which can mimic infections, malignancies, and even genetic disorders. Common symptoms at presentation are joint pain, fever, weight loss, malaise, muscle weakness, rash, and ulcers. While diseases, such as juvenile idiopathic arthritis, juvenile dermatomyositis, and IgA vasculitis, are relatively easy to diagnose because of typical clinical manifestations, others such as systemic lupus erythematosus, scleroderma, and various vasculitides are much more challenging. No laboratory investigation is diagnostic of a particular rheumatological disorder. Investigations, such as antinuclear antibodies and antineutrophilic cytoplasmic antibodies, are associated with a high false-positive rate and should be used judiciously. Most diseases except for Kawasaki disease and IgA vasculitis are chronic and require long-term immunosuppression for control of disease activity. Long-term prognosis has improved over the past few decades due to better immunosuppressive regimens and better monitoring. With an improvement in mortality rates, many children are living into adulthood and facing issues with persistent disease activity and morbidity related to therapeutic regimens. Future research should focus on finding better therapeutic protocols, which should result in further improvements in survival while simultaneously reducing drug toxicity. There is also an urgent need to define better monitoring tools for most rheumatological conditions.

Keywords: ANCA associated vasculitis, Antiphospholipid syndrome, IgA vasculitis, Juvenile dermatomyositis, Juvenile idiopathic arthritis, Juvenile systemic sclerosis, Kawasaki disease, Localized scleroderma, Macrophage activation syndrome, Neonatal lupus, Polyarteritis nodosa, Rheumatological disorders, Systemic lupus erythematosus, Takayasu arteritis, Uveitis, Vasculitis.

RHEUMATOLOGICAL DISEASES IN CHILDREN

Rheumatological diseases pose a real challenge to physicians because of multiple reasons. Signs and symptoms may either be non-specific like fever, weight loss,

* Corresponding author Anju Gupta: Department of Pediatrics, Advanced Pediatrics Centre, Postgraduate Institute of Medical Education and Research, Chandigarh, India; Tel: +91-7087008315; Fax: 91-172-2745078; E-mail: anjupgi@gmail.com

malaise, rash, and joint pains or may point to any organ system in the body. For this reason, these patients may present to any subspecialty of pediatrics. The differential diagnosis in such settings is wide, ranging from infections, inflammatory conditions, malignancies, and sometimes even genetic disorders.

Common manifestations with which patients are brought to pediatric rheumatological services are joint pain, fever, weight loss, malaise, muscle weakness, rash, and ulcers. This chapter will discuss the differential diagnosis of common rheumatological symptoms before discussing specific rheumatological conditions and their management.

When to Suspect Rheumatologic Disorders

Approach to a Child with Joint Pains

Joint pain is the most common symptom of children presenting to pediatric rheumatology services. Physicians need to be able to answer the following three questions after history and physical examination in children presenting with body pains:

1. Whether the pain is articular or not?
2. If articular,
 - a. Is the pain inflammatory or non-inflammatory?
3. In case of inflammatory articular pain
 - a. Is the involvement acute or chronic?
 - b. The pattern of joint involvement: Number of joints involved, symmetry of involvement, peripheral *vs.* axial involvement, small *vs.* large joint involvement, fixed *vs.* migratory *vs.* additive involvement.
 - c. Presence or absence of extra-articular features.

These three questions help in the further differential diagnosis. Pediatric gait, arms, legs, and spine (pGALS) test is a useful screening tool for musculoskeletal examination [1]. Though it is not specific to joint disease, it has been shown to improve musculoskeletal examination skills. Detection of any abnormality in pGALS should be followed by a detailed and focused examination of joints and supporting structures.

Whether the Pain is Articular or Not?

Articular pain tends to occur across joint lines, whereas the location of non-articular pain may vary. Articular pain is usually deep, diffuse, occurs along all planes of movement, and occurs on both passive and active movements (Table 1). Such pain suggests pathology in the synovium, cartilage, and joint capsule.

Table 1. Differences between articular and periarticular pain.

Clinical Feature	Articular Pain	Periarticular Pain
Anatomic structure	Synovium, cartilage, capsule	Tendon, bursa, ligament, muscle, bone
Location of pain	Diffuse, deep	Focal “pin-point”
Pain on movement	Active/passive, in all planes	Active, in a few planes
Swelling	Common	Uncommon; focal if present

On the other hand, periarticular pain is more focal, rather pinpoint, and occurs in few planes. Periarticular pain gets exacerbated with active movements. Such pain is seen due to pathology in tendons, bursa, ligaments, muscles, or bone. Common etiologies are enthesitis, fractures, and osteomyelitis in the metaphyseal region.

Is the Pain Inflammatory or Non-inflammatory?

Inflammatory pain is associated with early morning stiffness and gelling. Early morning stiffness refers to pain and difficulty in moving the joints in the morning on waking up, and it usually tends to last for half an hour or more. Gelling is similar to early morning stiffness but tends to happen after prolonged rest in the daytime. Joint swelling (Fig. 1) is also indicative of joint inflammation. Redness over the joint is rarely seen except in septic arthritis and reactive arthritis. Warmth and limitation of movement of joints also point to inflammatory causes (Table 2).



Fig. (1). Joint swelling in both knees suggestive of arthritis.

Updates on Common Oral Diseases in Children

Heliya Ziaei^{1,2}, Shahrzad Banan³ and Donya Alinejhad^{4,*}

¹ Network of Immunity in Infection, Malignancy and Autoimmunity (NIIMA), Universal Scientific Education and Research Network (USERN), Tehran, Iran

² Maxillofacial Surgery & Implantology & Biomaterial Research foundation, Tehran, Iran

³ School of Dentistry, Guilan University of Medical Sciences, Rasht, Iran

⁴ Department of Pediatric Dentistry, School of Dentistry, Tehran University of Medical Sciences, Tehran, Iran

Abstract: Oral and dental diseases are among the most common problems in children worldwide. If these problems remain untreated, they can have long-term effects on the orofacial system, chewing and speaking abilities, oral health-related quality of life, and overall health status. Dental caries, periodontitis and gingivitis, dental malocclusion, dental trauma, and some oral soft tissue lesions are among the most common oral disorders in children. Early diagnosis and management of these conditions by pediatric dentists and pediatricians necessitate being aware of the clinical manifestations of each disease at every age. Implementing preventive intervention, accurate diagnosis, proper treatment, and performing regular follow-ups are among the key factors for eliminating harmful long-life consequences of poor oral and dental health status in children and adolescents.

Keywords: Aphthous ulcer, Bruxism, Childhood caries, Children, Cyst, Dental caries, Eruption hematoma, Gingivitis, Hemangioma, Infection, Lip biting, Lymphangioma, Malocclusion, Oral habits, Periodontitis, Thumb sucking, Tongue, Tongue thrusting, Tooth, Trauma.

INTRODUCTION

Oral and dental diseases are among the most common problems in children worldwide. If these problems remain untreated, they can have long-term effects on the orofacial system, chewing and speaking abilities, oral health-related quality of life, and overall health status. Pediatric dentists and pediatricians should be aware of the signs and symptoms of these oral conditions for accurate diagnosis from the early steps and proper management to prevent further harmful consequences in the overall health status.

* Corresponding author Donya Alinejhad: Department of Pediatric Dentistry, School of Dentistry, Tehran University of Medical Sciences, Tehran, Iran; Tel: 00989153046375; E-mail: donya_alinejhad@yahoo.com

DENTAL CARIES

Dental caries is the most common chronic infection among children worldwide; *Streptococcus mutans* bacteria are considered the main etiological factor for this common oral disease [1]. According to the World Health Organization (WHO), in 2020, more than 530 million children suffer from dental caries of deciduous teeth; also, permanent teeth dental caries are the most common health issue based on a global assessment of 354 diseases in 2017 [2]. The DMFT index indicates the number of permanent teeth decayed, missing, and filled teeth, which is used as a global index for evaluating dental caries conditions worldwide. Due to the fact that this major public health issue is completely preventable, public health policymakers paid significant attention to implementing strategies to prevent this disease from childhood [3].

Early Childhood Caries (ECC) is one of the major public health problems worldwide; its prevalence is 12-27% among 2 to 3-year-old children, and it reaches 48% in up to 6 years old children. ECC is defined as “the presence of one or more decayed (non-cavitated or cavitated lesions), missing (due to caries), or filled tooth surfaces in any primary tooth in a child under the age of six” [4, 5]. This early onset disease can have major long-term consequences during the lifetime, such as premature teeth loss, future orthodontic problems, speech difficulties, masticatory and chewing issues, higher risk of further carious lesions in permanent teeth, impact on the development and eruption of permanent dentition, and orofacial dysfunction [6]. Thus, it has become one of the priorities of planning preventive interventions among public health managers.

ECC has multifactorial etiology, such as socio-economic status, dietary factors, behavioral problems, and genetic factors [4]; however, inadequate dental plaque removal of the primary teeth in addition to a sugary diet leads to accelerating this process [7]. One of the most prevalent examples of a sugary diet is prolonged usage of baby bottles with sugary contents, especially during the sleep period [4]. Based on a systematic review and meta-analysis, ECC's most important risk factors in high-income families were frequent sweetened meals, improper oral health care, and visible plaque in the oral cavity [8].

However, ECC can involve all primary teeth; it usually involves maxillary incisors (compared to mandibular incisors), followed by molars and canines, consequently (Figs. 1, 2A, 2B and 3) [9]. One of the most significant characteristics of ECC is the rapid progression of initial white spot lesions in the gingival margin to cavitated lesions in the labial or lingual surfaces of the primary teeth, which is not common in the routine form of tooth decay at this age [4, 9].



Fig. (1). ECC involving anterior maxillary incisors in a 5-years-old male child.



Fig. (2). **A.**ECC involving almost all primary teeth of 3-years-old children. The central and lateral primary incisors have severe tooth caries leading to complete disruption of the lateral crowns. **B.**ECC in the anterior maxillary incisors in a 4-years-old female patient.



Fig. (3). Cavitated untreated tooth caries in the second primary molar of a 6-years-old child.

Updates on Pediatric Metabolic Syndrome

Caroline Brand¹, Cézane P. Reuter¹ and Roya Kelishadi^{2,3,*}

¹ Graduate Program in Health Promotion - University of Santa Cruz do Sul, Santa Cruz do Sul, Rio Grande do Sul, Brazil

² Child Growth and Development Research Center, Research Institute for Primordial Prevention of Non-Communicable Disease, Isfahan University of Medical Sciences, Isfahan, Iran

³ USERN Office, Research Institute for Primordial Prevention of Non-Communicable Disease, Isfahan University of Medical Sciences, Isfahan, Iran

Abstract: Metabolic Syndrome (MetS) is considered as the presence of clustering metabolic risk factors. It is rapidly increasing in children and adolescents, notably in low- and middle-income countries. It results from a complex interaction of lifestyle, environmental, and genetic factors. Although its universal definition needs to be determined in the pediatric age group, the main components are obesity, dyslipidemia in terms of elevated triglycerides, and elevated blood pressure. Respectively, fatness and fitness have a direct and inverse association with the development of MetS. Various metabolic responses that are involved in the adipose tissue promote a link between obesity, insulin resistance, inflammation, and future atherogenesis. Management of pediatric MetS would need multidisciplinary interventions, including a multicomponent approach, consisting of healthy eating, reducing screen time, increasing physical activity, as well as providing appropriate duration and quality of sleep. Limiting the exposure of pregnant mothers as well as children and adolescents with endocrine disrupting chemicals is beneficial for preventing the development of MetS. Lifestyle modification and family-centered interventions are the first-line approaches in the treatment of MetS, and the use of medication should be considered only for those who fail to reach healthy weight after lifestyle intervention and for those with underlying disease and complications. Prevention and early management of pediatric MetS are of main strategies for primordial/primary prevention of non-communicable diseases.

Keywords: Children and adolescents, Environment, Epigenetics, Lifestyle, Metabolic syndrome, Prevention.

* **Corresponding author Roya Kelishadi:** Child Growth and Development Research Center, Research Institute for Primordial Prevention of Non-Communicable Disease, Isfahan University of Medical Sciences, Isfahan, Iran and USERN Office, Research Institute for Primordial Prevention of Non-Communicable Disease, Isfahan University of Medical Sciences, Isfahan, Iran; Tel: +983136691216, 37923321; E-mail: kelishadi@med.mui.ac.ir

INTRODUCTION

Metabolic Syndrome (MetS) is characterized as clustering of cardiometabolic risk factors. Although there is no uniform agreement regarding the diagnostic criteria for MetS among children and adolescents, most of the available definitions agree that hypertension, glucose intolerance, central obesity, and dyslipidemia should be included as the main components [1, 2]. In this context, obesity plays a central role, as it represents the main risk for developing metabolic alterations [3].

The prevalence of MetS has increased in the paediatric population in recent years as a result of improper lifestyle habits along with the development of early risk factors [4, 5]. Healthy behaviors, such as regular physical activity practice, healthy diet, adequate sleep patterns, as well as an active routine must be incorporated at an early age, once they are closely related to the development of metabolic complications [6, 7]. In addition, prenatal and postnatal environmental factors, including birth weight, obesity during pregnancy, gestational diabetes, as well as breastfeeding duration, have been considered relevant aspects for the onset of obesity and MetS [8 - 10].

Pediatric MetS is a predictor of this condition in adulthood [11], highlighting the need for the early management of this disease. As the first-line approach, the treatment includes interventions to promote adequate nutrition and physical activity practice, in which multicomponent interventions are the most effective [12, 13]. If this strategy does not result in beneficial effects, pharmacological treatment can be incorporated [14].

Therefore, MetS is a complex disorder that develops at an early age, necessitating the implementation of public health policies to prevent and treat it. Taking these aspects into consideration, this chapter aims to approach the factors associated with MetS development, prevention, and treatment in the pediatric age group.

DEFINITION AND PREVALENCE

MetS is recognized as an important health risk in children and adolescents [15]. It is characterized by a clustering of metabolic abnormalities that result in increased risk for the development of chronic diseases, mainly cardiovascular disease and type II diabetes [16]. In the pediatric age group, studies are proposing a set of different criteria to define MetS, and although there is no consensus among them, the diagnosis criteria agree that some essential components are present, such as glucose intolerance, central obesity, hypertension, and dyslipidemia [1, 17, 18].

In the absence of definitive definitions, adult criteria have been adapted to be applied in the field of pediatrics, and one of the most commonly used is the one

proposed by the International Diabetes Federation (IDF) [1]. According to this group, the parameter required for the MetS diagnosis is the presence of three or more of the following criteria: waist circumference $\geq 90^{\text{th}}$ percentile, systolic blood pressure ≥ 130 mmHg; diastolic blood pressure ≥ 85 mmHg; triglycerides ≥ 1.69 mmol/L; high-density lipoprotein cholesterol (HDL-C) ≤ 1.03 mmol/L; fasting glucose ≥ 5.55 mmol/L. Another widely used definition is the one adapted from the Adult Treatment Panel III (ATP III) [2], in which MetS is defined by the presence of three or more of the following components: waist circumference $\geq 90^{\text{th}}$ percentile for age and gender; elevated systolic and/or diastolic blood pressure $\geq 90^{\text{th}}$ percentile for age, sex, and height; triglycerides ≥ 1.24 mmol/L; HDL ≤ 1.03 mmol/L; impaired fasting glucose ≥ 5.6 mmol/L. Although these definitions included the same components, they considered different cut-points for elevated blood pressure and hypertriglyceridemia. Also, the IDF criteria are suitable only for children 10 years or older, while the ATP III can be used for children below the age of 10 years.

There are important limitations attributed to these traditional criteria. Using a binary classification, it is only possible to determine the presence or the absence of the risk factor, which can lead to a lack of durability in the classification, mainly considering the individuals near the limit of individual cut-offs. The instability in the categorical diagnosis of MetS has been shown in studies developed with children and adolescents [19, 20]. Another limitation concerns the disregard of the influence of sex and ethnicity [21].

To overcome these barriers, it has been suggested that the components of MetS should be considered as continuous variables [22, 23]. Thus, several studies have proposed a continuous score to represent the clustering of MetS components, which is justified by the notion that this approach could be less error susceptible compared to the dichotomic one [24]. Additionally, it would provide full information on the health status and is more reliable in predicting young adult cardiovascular risk from childhood [25].

In addition to the traditional elements, some researchers have proposed that other components should be included in MetS diagnosis. According to Andersen *et al.* (2015), the inclusion of cardiorespiratory fitness and leptin could improve the diagnostic criteria. Furthermore, the consideration of non-alcoholic fatty liver disease, hyperuricemia, leptin/adiponectin ratio, and sleep disturbances have also been argued once are related to risks for metabolic impairment [15, 26].

The lack of a universal definition and the different characteristics between populations result in the varying MetS prevalence. A study developed with Chinese schoolchildren compared two definitions and showed that the prevalence

Updates on Pediatric Epilepsy Syndromes

Ahmed Nugud^{1,*}, Alaa Nugud², Assmaa Nugud³ and Shomous Nugud⁴

¹ Al Jalila Children's Specialty Hospital, Dubai, UAE

² Latifa Women's and Children's Hospital, Dubai Health Authority, Dubai, UAE

³ Ras Al Khaimah Medical and Health Sciences University, Ras Al Khaimah, UAE

⁴ University of Sharjah, Sharjah, UAE

Abstract: This chapter examines the basics of pediatric epilepsy syndromes and the new factors in the field that lead to and result from the disturbed function. Some disorders such as febrile seizures and idiopathic seizure disorders are fairly common in children, and pediatricians should be familiar with the approaches used to investigate such disorders. However, others, such as rare genetic diseases, are increasing in incidence due to the recent advances in genetic testing and personalized medicine. Nevertheless, epilepsy syndromes carry significant morbidity and even mortality in children. The advent of new genetic discoveries has also brought forth new lines of management for previously refractory diseases. The truly intractable epilepsy syndromes might be managed with surgery as a final resort.

Keywords: Absence seizures, Aura, Childhood epilepsy, Developmental delay, Dravet syndrome, Electrolyte disturbance, Encephalitis, Epilepsy neurosurgery, Febrile seizures, Generalized seizures, Genetic epilepsy, Metabolic epilepsy, Movement disorders, Non-epileptic seizures, Neurological evaluation, Partial seizures, Seizures syndromes, Seizures investigations, Seizures management, Status epilepticus.

INTRODUCTION

Diagnosing seizures is a challenge and should be considered with diligence, as in most cases, it confers a lifelong treatment and, in some cultures, is considered a stigma. A thorough and detailed medical history is paramount for the diagnosis of seizures and is the first step towards a detailed neurological assessment. Thus, history is the first step towards diagnosing pediatric movement disorders along

* Corresponding author Ahmed A. Nugud: Department of medical affairs, Al Jalila Children's Specialty Hospital, PO Box 7662, Dubai, UAE; Tel: +971509973764; E-mail: a7md13@gmail.com

with physical examination that guides the clinicians towards a diagnostic approach and eventually the formulation of a management plan.

The history should provide a chronological timeline to the chief complaint, focusing on signs and symptoms associated with the suspected seizure, duration of the episode, any possible post-seizure symptoms, events leading to the episode, and any alleviating or aggravating elements. Whenever possible, clinicians should seek video recording of alleged episodes to further look into the condition, as even a short film would carry more information for the trained eyes than a lengthy description by a parent or a caregiver [1].

An integral part of the complete history of newly onset seizures is a review of systems, specifically looking for; 1) history of other symptoms that might be misattributed to other systems (*e.g.*, vomiting, fatigue, aura), 2) systemic illness that might lead to central nervous system manifestations (*e.g.*, lupus, metabolic diseases, mitochondrial disorders), 3) Possible infectious etiologies (*e.g.*, rheumatic fever, respiratory infections, urinary tract infections), 4) possible toxins exposure/poisoning (*e.g.*, lead exposure, pesticide exposure, neuropsychiatric medications ingestion). Auras can present in different formats, including 1) visual (color changes, flashing lights, seeing floaters and visual hallucinations), 2) tactile, 3) auditory, 4) olfactory, 5) others (*e.g.*, déjà vu, vestibular changes)

Detailed birth history must be obtained; this will further elucidate any risk of perinatal acquired conditions. This part starts with history prior to conception and follows till the end of the neonatal period. Clinicians should ask specifically about common pregnancy-related complications, including 1) adequate supplements intake during pregnancy, 2) perinatal follow up (and whether any concerns were raised about pregnancy-induced hypertension, preeclampsia, gestational diabetes, and infections), 3) gestational age at delivery and mode of delivery, 4) admission to neonatal intensive care and the reasons (if any), 5) quantify drug intake during pregnancy (including alcohol, prescription and illicit drugs, smoking, and any herbal remedies usage during pregnancy), 6) nature of fetal movement during pregnancy, 7) birth parameters (weight, length, and head circumference) should be noted, 8) if the patient had developed neonatal jaundice (in such case the clinician should inquire about the highest recorded level of bilirubin and mode of treatment), and 9) newborn screening results can also provide clues to neurological manifestations of metabolic disease. Obtaining medical records of patients might provide further insight into past medical history and possible etiologies for newly onset seizures [2].

A developmental history is an important tool in the diagnostic approach to newly onset seizures, especially if there are concerns about delay in acquiring skills or, more ominously, if a patient has lost skills. The knowledge about the range of time to skill acquisition and mastery are indispensable tools to correct diagnosis of newly onset seizures. Table 1 summarizes developmental milestones for the first 2 years.

Table 1. Expected developmental milestones and age of acquisition in the first two years of life.

Age	Gross Motor	Fine Motor	Speech / Language	Cognitive / Problem Solving	Social / Emotional
Newborn	Primitive reflexes – steps, place, Moro, Babinski, ATNR, Flexor posture	Primitive reflexes – grasp	Primitive reflexes – root, suck Alerts to sound Startles to loud sounds Variable cries	Visual focal length – 10 degrees Fix and follow slow horizontal arc Prefers contrast, colours, face Prefers high pitched voice	Bonding (parent -> child) Self-regulation/soothing
2 months	Head steady when held Head up 45 degrees prone	Hands open half of the time Bats at objects	Turns to voice Cooing	Prefers usual caregiver Attends to moderate novelty Follows past midline	Attachment (child -> parent) Social smile
4 months	Sits with support Head up 90 degrees prone, arms out Rolls front -> back	Palmar grasp Reaches and obtains items Brings object to the midline	Laugh, razz, “ga”, squeal	Anticipates routines Purposeful sensory exploration of objects (eyes, hands, mouths)	Turn-taking conversations Explores parent's face
6 months	Postural reflexes Sits tripod Rolls both ways	Raking grasp Transfers hand to hand	Babbles (nonspecific)	Stranger anxiety Looks for dropped or partially hidden object	Expresses emotions: happy, sad, mad Memory lasts – 24 hours

Updates on Pediatric Genetic Epileptic Encephalopathies: A Diagnostic Algorithmic Approach

Vikas Dhiman^{1*}, Shwetha Chiplunkar² and Rajnarayan R Tiwari³

¹ Department of Environmental Health and Epidemiology, ICMR-National Institute for Research in Environmental Health (NIREH), Bhopal, Madhya Pradesh-462030, India

² Department of Pediatrics, Maidstone and Tunbridge Wells NHS Trust, Kent county-ME16 9QQ, United Kingdom

³ ICMR-National Institute for Research in Environmental Health (NIREH), Bhopal, Madhya Pradesh-462030, India

Abstract: Epileptic Encephalopathies (EEs) are a heterogeneous group of epilepsy syndromes predominantly seen in neonatal, infantile, and childhood age groups. EEs present with varied signs and symptoms often pose a diagnostic dilemma for the treating physician. The diagnostic complexities imposed by variable age of presentation and overlapping clinical signs and symptoms in EEs are further increased by exhaustive new information from advanced molecular genetic techniques like next-generation sequencing. Taking into account all these challenges, the main objective of this chapter is to briefly outline important diagnostic signs and symptoms, EEG, imaging and genetic findings of common neonatal, infantile and childhood-onset genetic epileptic encephalopathies, and secondly, to draw a simple and pragmatic diagnostic algorithm for the diagnosis of genetic epileptic encephalopathies by the treating physicians. Systematic diagnostic algorithms of commonly occurring EEs would not only guide physicians regarding the management of the patients but also help to counsel parents regarding the prognosis, risk of inheritance, and prenatal testing.

Keywords: Algorithm, Diagnostic, Dravet, Drug-resistant, Epileptic, Encephalopathies, Febrile, Genetics, Infantile, Landau-Kleffner, Lennox-Gastaut, Molecular, Myoclonic, Neonatal, Ohtahara, Pediatric, Semiology, Syndrome, Treatment, West-syndrome.

* **Corresponding author Vikas Dhiman:** Department of Environmental Health and Epidemiology, ICMR-National Institute for Research in Environmental Health (NIREH), Bhopal, Madhya Pradesh, India; Tel: +919501074334
Emails: drvikasdhiman.nimhans@gmail.com, dhiman.vikas@icmr.gov.in

INTRODUCTION

Seizures in childhood are one of the commonest neurological symptoms encountered in clinical practice, and they range from a benign single seizure episode to intractable epilepsy and encephalopathy [1]. Epileptic encephalopathies (EEs) are devastating conditions characterized by drug-resistant generalized or focal seizures, electroencephalographic (EEG) abnormalities, and impaired cognitive, sensory, and motor development. It is reported that 40% of all seizures during first three years of age are due to EEs. The majority of children with EEs become resistant to available antiepileptic drugs (AEDs) and are prone to premature deaths, injuries, and poor quality of life. The underlying etiologies of EEs remain heterogeneous, ranging from idiopathic to potentially morbid genetic variants.

It has been found in a recent study that a genetic cause could be attributed in 28% of the children with EEs based on the diagnostic genetic testing [2], highlighting the complexity involved in making the diagnoses of EEs. Early diagnosis and therapeutic interventions are vital as these can alter the course of the disease and improve the final outcome. Considering a significant overlap and complexity among signs and symptoms seen in children with EEs and the difficulties associated with making an early diagnosis of EE, the main objectives of this chapter are a) to briefly outline important signs and symptoms, EEG, imaging, and genetic findings of common neonatal, infantile and childhood genetic epileptic encephalopathies, and b) to draw a simple and pragmatic algorithm for the diagnosis of genetic epileptic encephalopathies.

NEONATAL EPILEPTIC ENCEPHALOPATHIES

Neonatal Epileptic Encephalopathies (NEE) is an autosomal dominant, severe form of encephalopathy where seizures start as early as the first week of life [3]. Infants predominantly develop tonic seizures with associated autonomic features that remain recurrent and refractory to conventional antiepileptic medications. Sodium channel blockers like carbamazepine and phenytoin have shown some benefits and are considered first-line treatment. Ictal EEG typically shows a burst suppression pattern or multifocal epileptiform activity. Brain imaging shows hyperintensities in bilateral basal ganglia and thalamus that usually resolve by the age of three. Seizure cessation occurs anytime between nine months to four years of age but ensues a lasting neurological sequel with moderate to severe developmental delay in all domains [4]. EEG usually becomes normal with control in seizures [5]. *KCNQ2* (voltage-gated potassium channel) is implicated in this disorder harboring a heterozygous missense pathogenic mutation.

Another EE subtype, Benign Familial Neonatal Epilepsies (BFNE), is a rare form of epilepsy presenting in the early neonatal period. The onset is typically between the second to the eighth day of life. These infants develop brief but sometimes recurrent seizures that include tonic or apneic seizures, focal clonic activity, and autonomic symptoms. They are amenable to conventional antiepileptic medications and leave no neurological sequel. All laboratory investigations, including brain imaging, are normal [6]. Ictal EEG shows focal discharges that may secondarily generalize. Inter-ictal EEG is usually normal, rarely it shows ‘theta pointu alternant’ activity, characterized by dominant theta activity, non-reactive, inter-hemispheric asynchrony, and sharp waves. BFNE is autosomal dominant genetic epilepsy with mutations in *KCNQ2*, coding for a subunit of the voltage-gated potassium channel in the brain [7]. A heterozygous pathogenic variant (60-80% cases) [8] or deletion/duplication (20-40% cases) [9] in *KCNQ2* can cause the disease with a penetrance of 77-85% [5]. A minority of infants with BFNE harbored mutations in *KCNQ3*, a close homolog of *KCNQ2*, and one family harbored pericentric inversion of chromosome 5 [10]. BFNE has a good prognosis with spontaneous resolution of seizures by twelve months of age with no lasting sequel.

Ohtahara Syndrome

The seizure onset is specifically in the neonatal or early infantile period. The majority of seizures are present in the first month of life with recurrent episodes of tonic spasms, sometimes in clusters. There can also be associated generalized seizures, hemiconvulsions, and focal seizures but tonic spasms are more consistently observed in Ohtahara syndrome. Interestingly, myoclonic epilepsy has not been associated with Ohtahara syndrome [11]. The seizures can be similar to West syndrome (see below), but the age at onset, occurrence of seizures in both awake and sleep states, and specific EEG changes, differentiate it from West syndrome [12]. Clinically, Ohtahara syndrome is characterized by daily, recurrent seizures, with significant psychomotor delay and a poor prognosis. The characteristic EEG abnormality is the suppression burst pattern with sudden high voltage bursts alternating with flat records denoting the suppression. These alternations occur periodically in both awake and sleep states, differentiating it from West syndrome, which shows remarkable periodicity in sleep. The most common underlying pathology has been structural brain abnormalities like cerebral dysgenesis and cortical malformations. Ohtahara syndrome in a majority of cases progresses to West syndrome, as reported by a longitudinal study [13]. Ohtahara syndrome has poor prognosis with intractable seizures and significant psychomotor delay. Treatment trials with ACTH injections, clonazepam, ketogenic diet, and vitamin B6 supplementation have not shown any significant benefit [14].

Updates on Pediatric Demyelinating Disorders

Amit Agrawal^{1,*} and Umesh Pandwar¹

¹ Department of Pediatrics, Gandhi Medical College & Hamidia Hospital, Bhopal, MP 462001, India

Abstract: Myelin is a protective layer that enwraps the axonal terminals and is an essential component of the central nervous system white matter. Loss of myelin leads to conduction block in the axon leading to demyelinating disorders. Inherited poor formation of myelin is known as *hypomyelination*, and abnormally formed myelin is called *dysmyelination*. Demyelinating disorders exclude diseases where degeneration of the axon is the initial event and myelin is degraded secondarily. Most neurologists use the term *demyelination only for* acquired forms of loss of myelin with relative preservations of axons due to inflammation such as multiple sclerosis. Demyelinating disease in children may be monophasic (*e.g.*, acute disseminated encephalomyelitis, optic neuritis, and transverse myelitis) or chronic (multiple sclerosis and neuromyelitis optica). Pediatric multiple sclerosis is the most common demyelinating disorder in children. Recent genetic and clinical researches have significantly improved our understanding of the diverse spectrum of pediatric demyelinating disorders. In this chapter, an updated summary of the current knowledge on the categories, diagnosis, as well as management of pediatric demyelinating disorders has been presented.

Keywords: Adolescent, Central Nervous System/immunology, Central Nervous System/pathology, Child, Demyelinating Diseases/diagnosis, Demyelinating Diseases/drug therapy, Demyelinating Diseases/immunology, Demyelinating Diseases/pathology, Encephalomyelitis, Acute Disseminated / cerebrospinal fluid, Encephalomyelitis, Acute Disseminated/diagnosis, Humans, Magnetic Resonance Imaging, Multiple Sclerosis/cerebrospinal fluid, Multiple Sclerosis/diagnosis, Multiple Sclerosis/drug therapy, Myelin-Oligodendrocyte Glycoprotein / immunology, Neuromyelitis Optica/cerebrospinal fluid, Neuromyelitis Optica/diagnosis, Neuromyelitis Optica/drug therapy, Serologic Tests, Treatment Outcome.

* Corresponding author Amit Agrawal: Department of Pediatrics, Gandhi Medical College & Hamidia Hospital, Bhopal, MP 462001, India; Tel: +91-9826616019; E-mail: agrawaldramit@yahoo.co.in

INTRODUCTION

Axonal terminals, cylindrical processes that arise from the axon hillock of every neuron, have synaptic connections with other neurons. Myelin is a protective layer that enwraps these axonal terminals and is an essential component of the central nervous system (CNS) white matter. Myelin is an extended component of the cell membrane in the nervous system and is divided into segments over the length of specialized nerve fibers. It works as an insulator to prevent loss of action potential current and increases the transmission velocity of stimulus in nerve fibers by decreasing membrane capacitance so that the charges are not able to accumulate at a point. The transmission speed of the action potential is faster in myelinated neurons as compared to unmyelinated ones. Myelin in CNS is produced by oligodendrocytes, and in PNS, it is produced by Schwann cells.

Myelin loss leads to conduction block in the axon by increasing membrane capacitance, accumulation of charges at the point of lost myelin, and slowing down the rate of nerve impulses transmission, thereby results in derangement of the neurologic functions [1]. The absence of myelin may be acquired or inherited. Inherited disorders of poorly formed myelin are known as hypomyelination disorders, and abnormally formed myelin is called dysmyelination [2].

Demyelinating disorders exclude those diseases where degeneration of axon is the initial event and myelin is degraded secondarily [3]. Most neurologists use the term *demyelination only for* acquired forms of myelin loss with relative preservations of axons due to inflammation such as multiple sclerosis [4]. Acquired disorders of demyelination are due to inflammation or immune-mediated destruction of normally formed myelin [5]. Poser also termed this group of myelin disorders as “demyelinating or myelinoclastic diseases” [6]. Acquired disorders of demyelination due to inflammation comprise both the central (CNS) and peripheral nervous system (PNS) myelin disorders. These are rare disorders with an incidence of 0.5-1.66 per 100,000 children per annum [7]. Demyelination is often preceded by an infectious illness, ischemic attack, or maybe due to a metabolic or hereditary defect. The cause of disorders that primarily affect myelin is idiopathic or unknown but may be due to the autoimmune process [8]. The wide spectrum of neurological signs and symptoms are covered by acquired demyelinating disorders due to myelin damage caused by inflammation (Table 1).

Table 1. Causes of Acquired disorders of CNS demyelination.

Hypoxia and Ischemia	-
Nutritional Deficiencies	Vitamin B12 Deficiency

(Table 3) cont....

Viral infection of CNS	Progressive multifocal leukoencephalopathy, Subacute sclerosing panencephalitis, Tropical spastic paraparesis/ HTLV-1-associated myelopathy
Primary demyelinating disorders	Monophasic - optic neuritis, acute transverse myelitis, acute disseminated encephalomyelitis Recurrent, progressive disorders – multiple sclerosis, neuromyelitis optica
Toxins and drugs	Alcohol, Carbon monoxide, Ethambutol

CLASSIFICATION OF PEDIATRIC DEMYELINATING DISEASES

Pediatric demyelinating disorders are generally classified as either monophasic (single episode) or polyphasic illness (relapses). In children, most of the demyelinating disorders present with monophasic illness are without any relapse. Monophasic forms of demyelinating disorders in children include acute disseminated encephalomyelitis, transverse myelitis, and optic neuritis. Multiple Sclerosis and neuromyelitis optica spectrum disorder are relapsing or polyphasic forms of demyelinating disorders. On the basis of signs and symptoms' localization, demyelinating disorders can be monofocal if a single lesion can be attributed for manifestations and polyfocal if multiple site lesions are required to explain signs and symptoms [9].

Acute Disseminated Encephalomyelitis

Acute Disseminated Encephalomyelitis (ADEM) is the clinical event of acute inflammatory demyelinating lesions on brain MRI with poly focal neurological deficits in nature and accompanying encephalopathy. ADEM usually presents in early childhood [10 - 12].

Epidemiology

The incidence is 0.1-0.6 per 100,000 per year in children. A study conducted on Canadian children showed an estimated annual incidence of 0.2 per 100,000 [13]. The seasonal pattern of ADEM is seen in North America, with a peak in winter and spring [14, 15]. There is a slight male predominance [16, 17]. The mean age of ADEM presentation is between 5 and 8 years but can occur at any age [18 - 20]. Recurrence is less common as the disease is usually monophasic. The term *multiphasic disseminated encephalomyelitis (MDEM)* is used when recurrence occurs after 3 months of the first event. In ADEM, Myelin oligodendrocyte glycoprotein antibodies (MOG- Ab) are present in the serum of 50% of children [21 - 23]. MOG-Ab antibodies are present in the serum of all cases of MDEM. Multiple Sclerosis (MS) should be suspected if an episode of non- ADEM demyelination affecting a new location occurs after an episode of ADEM and

Updates on Atopic Dermatitis

Edna Morán-Villaseñor¹ and María Teresa García-Romero^{1,*}

¹ Department of Dermatology, National Institute of Pediatrics, Insurgentes Sur 3700-C, Mexico City 04530, Mexico

Abstract: Atopic dermatitis (AD) or atopic eczema is a complex and multifactorial chronic inflammatory skin disease that is characterized by intense itching and recurrent eczematous lesions. It is very frequent, affecting up to 20% of children in developed countries, and its prevalence has increased worldwide. Patients with AD have an increased risk of developing food allergy, allergic rhinitis, and asthma later in life; but may also present other comorbidities. The main symptom of AD is pruritus, which along with sleep disturbance, decreases the quality of life not only in patients but also in their families. Therapeutic options for AD have historically been limited, but recent advances have increased our understanding of its underlying mechanisms, contributing to the development of new therapies. In this chapter, we review the most recent knowledge about etiology, pathophysiology, clinical manifestations, comorbidities, and treatment options of AD.

Keywords: Atopic Dermatitis, Atopic Eczema, Atopic Neurodermatitis, Disseminated Neurodermatitis, Infantile Eczema, Pediatrics, Quality of life.

INTRODUCTION

Atopic dermatitis (AD) -also known as atopic eczema- is a chronic inflammatory skin disease that is characterized by intense itching and recurrent eczematous lesions. AD affects 10 to 20% of children in developed countries, and its prevalence has increased worldwide [1]. Several studies have demonstrated that the presence of AD increases the risk of developing food allergy, allergic rhinitis, and asthma later in life [2, 3]. Comorbidities, pruritus, and sleep disturbance significantly decrease quality of life not only in patients but in their families as well [4]. AD is complex and multifactorial, with historically limited therapeutic options, but significant recent advances have increased our understanding of the underlying mechanisms of AD, contributing to the development of new therapies.

* Corresponding author María Teresa García-Romero: Department of Dermatology, National Institute of Pediatrics, Insurgentes Sur 3700-C, Mexico City 04530, Mexico; Tel: 52-55-1084-0900; Ext. 2034; E-mail: teregarro@gmail.com

EPIDEMIOLOGY

There are two main challenges when evaluating the epidemiology of AD: first, there are no widely accepted biomarkers or objective diagnostic tests for AD; and second, there is a lack of standardized nomenclature for AD which makes it difficult to develop consistent questionnaires for epidemiology research [5].

Overall, it is considered that AD affects 10 to 20% of children in developed countries and that its prevalence has increased worldwide in the past 30 years [1, 6, 7]. Prevalence estimates of childhood AD in the United States range from 6% to 12.97%, depending on the study design and approach used [5, 8, 9]. The International Study of Asthma and Allergies in Childhood (ISAAC) is the biggest and only study that has taken a global approach; it provided a global map of AD and found a wide variation in prevalence values worldwide, from 2.0% in Iran to 22.3% in Sweden at ages 6 to 7 years and from 1.4% in China to 21.8% in Morocco at ages 13 years to 14 years [6]. The ISAAC also found a global increase in the prevalence of symptoms of eczema from 1994-1995 to 2002-2003 [6]. Data from the National Health Interview Survey (NHIS), a US population-based household survey, indicates that the prevalence of childhood AD steadily increased from approximately 8% in 1997 to more than 12% in 2010 [5]. Many hypotheses have been explored to explain this increase, including modulation of immune priming by hygiene, gut microbiota diversity, exposure to endotoxins through farm animals, and the effects of pollution, climate, and diet [7].

ETIOLOGY

The pathophysiology of atopic dermatitis is complex and not fully understood yet. It is proposed to be the result of an interaction of genetic and environmental factors that ultimately leads to impaired epidermal barrier function and immune dysregulation (Fig. 1) [10, 11].

IMPAIRED SKIN BARRIER FUNCTION

The most important function of the skin is to provide an effective barrier between the internal and external environments of an organism. The epidermal barrier limits passive water loss, restricts environmental chemical absorption, and prevents microbial infection. Therefore, any damage to the structure of the skin barrier enhances the penetration of allergens to the skin, increases transepidermal water loss (TEWL), and contributes to immune dysfunction [11, 12].




Fig. (1). Skin barrier abnormalities and immune dysfunction are the main features of atopic dermatitis (11).

Major contributors to an impaired skin barrier function include:

Decreased Filaggrin

Filaggrin (FLG) is a structural protein responsible for the keratinization, moisturization, and antimicrobial peptide functions of the skin. It is the main component of keratohyalin granules, and their breakdown products contribute to epidermal hydration and barrier function [13].

FLG can be broken down into free amino acids and converted into urocanic acid, which maintains the acidity level in the skin, and pyrrolidine carboxylic acid, which acts as a natural moisturizer. Mutations in FLG gene are associated with increased TEWL and dry skin in patients with AD [14].

However, 40% of FLG mutation carriers do not develop AD, and FLG mutations are only found in 10% of patients with AD [15]. Therefore, genetic abnormalities in FLG alone do not explain all the skin barrier dysfunctions of AD.

Updates on Henoch-Schonlein Purpura

Patricia Morán-Álvarez¹, Guillermo Santos-Simarro² and Fernando Santos^{3,4,*}

¹ Department of Rheumatology Hospital Universitario Ramón y Cajal, Madrid, Spain

² Department of Pediatrics Hospital Universitario La Paz, Madrid, Spain

³ Division of Pediatric Nephrology Hospital Universitario Central de Asturias, Oviedo, Asturias, Spain

⁴ Department of Medicine University of Oviedo, Oviedo, Asturias, Spain

Abstract: Henoch-Schönlein purpura (HSP), currently also known as immunoglobulin A (IgA) vasculitis, is the most common vasculitis in children. It is a systemic autoimmune disease mediated by complexes containing abnormal IgA. The cause of HSP is not well known, but the disease is often triggered by an upper respiratory infection in individuals with genetic susceptibility. The diagnosis relies on internationally agreed criteria, including palpable cutaneous purpura of orthostatic location associated with at least one of the following findings: arthralgia/arthritis, gastrointestinal manifestations, leukocytoclastic vasculitis with IgA deposits and/or renal involvement. The skin lesions are essential for the diagnosis. The digestive symptoms, mostly severe abdominal pain, intestinal bleeding, and more rarely, intussusception, maybe the initial and most worrisome clinical component of HSP during the acute presentation of the disease. Nephropathy determines the long-term prognosis. The clinical course of HSP is, in general, favorable. Bed rest results in remission of the purpura that often recurs as the child restarts standing and walking. Corticosteroids are effective, although not usually required, to treat abdominal pain and other severe manifestations. No medical treatment can avoid the possibility of renal involvement that may occur for several months after resolution of the skin lesions. Corticosteroids are used to treat severe forms of HSP nephropathy, which anatomopathologically corresponds to IgA glomerulonephritis. Active research studies are needed to clarify the pathogenesis, the prognostic factors, and the measures to be taken for the prevention and treatment of renal disease.

Keywords: Anaphylactoid purpura, Asialoglycoprotein receptor, β 1,3-galactosyltransferase, Childhood systemic vasculitis, Children, Galactose-deficient IgA1, Henoch-Schönlein purpura, IgA1 isoform, IgA vasculitis, IgA glomerulonephritis, IgAV nephropathy, IgG-Gd-IgA, Immune complexes, Leukocytoclastic vasculitis, Lower limb purpura, Non-granulomatous vasculitis,

* Corresponding author Fernando Santos: Nefrología Pediátrica, Pediatría. Hospital Universitario Central de Asturias, Avda de Roma s/n, 33011 Oviedo, Asturias, Spain; Tel: +34 985108237; E-mail: fsantos@uniovi.es

Pediatric purpura, Pediatric vasculitis, Rheumatoid purpura, Small vessel vasculitis.

INTRODUCTION

Systemic vasculitides are characterized by blood vessel inflammation, leading to tissue injury from vascular stenosis, occlusion, aneurysm, and/or rupture. These entities are rare in childhood but are associated with significant morbidity and mortality. Only Henoch-Schönlein purpura (HSP) and Kawasaki disease are relatively common in pediatric patients. HSP is the most common primary systemic vasculitis in children. It is a non-granulomatous form of systemic vasculitis that affects small vessels predominantly.

The term HSP comes from Johann Schönlein and Eduard Henoch, two German doctors who first made a detailed description of the disease in the 1860s [1]. Recent consensus documents have proposed replacing the name HSP with that of IgA vasculitis (IgAV), based on the pathophysiological feature of the disease [2]. Both denominations will be used in this chapter, as the term HSP is widely extended in the medical community and is commonly used in everyday clinical practice. Other nomenclatures such as anaphylactoid purpura and rheumatoid purpura have also been utilized. The association of cutaneous, musculoskeletal, and renal manifestations has led to consider HSP as the cause of the composer Wolfgang Amadeus Mozart's death in 1791, although scientific evidence supporting this hypothesis is missing [3].

According to the internationally accepted classification of vasculitis in childhood [4], the diagnosis of HSP or IgAV includes the mandatory presence of purpura or petechia with lower limb predominance and at least one of the four following criteria: abdominal pain, arthritis or arthralgia, renal involvement (proteinuria, hematuria or red blood cell casts), histopathology findings showing leukocytoclastic vasculitis or glomerulonephritis with predominant IgA deposit.

A detailed description of these criteria will be provided in this chapter. In adults, unlike children, there are no internationally agreed-upon criteria for the diagnosis of IgAV.

EPIDEMIOLOGY

HSP is typical of the pediatric age, although it can also be seen in adults. It is the most common vasculitis among children, the annual incidence having been estimated from 3 to 26.7/100 000 for children and infants and 0.8-1.8/100 000 for adults [5]. The incidence peak stands around 4-6 years, 90% of cases are younger than 10 years of age, and it is rare in infants. HSP is found in both genders with a preponderance of males and in all races, being less frequent in black people with

respect to white and Asian people [6]. There is seasonal variation likely linked to the variable incidence of upper respiratory tract infections [7].

PATHOGENESIS

HSP is a small vessel leukocytoclastic vasculitis of unclear pathogenic origin [8], the combination of genetic susceptibility and environmental risk factors (such as infections, food, vaccination, or drugs) being likely involved in the development of the disease [9].

Around 50% of HSP cases are preceded by an upper respiratory tract infection, suggesting this type of infection is the main trigger of the disease [10, 11], followed by gastrointestinal infections in 5-6% and urinary tract infections in 1%, approximately. Several infectious agents have been implicated, including *group A or B hemolytic Streptococcus*, *Staphylococcus aureus*, *parainfluenza*, *Helicobacter pylori*, *Parvovirus B19*, or *Epstein-Barr virus*, among others [11]. Some studies found *Streptococcus*, identified by anti-streptolysin (ASO) titer test and throat swab culture, as the most common infectious agent associated with HSP (around 30%) [9]. The relationship between several vaccines and HSP, including influenza A (H1N1) vaccination, has also been described [12].

As for the genetic component, HLA-DRB1*01, HLA-DRB1*11, and HLA-B*41:02 antigens have been proposed to be associated with an increased risk of developing HSP, whereas HLA-DRB1*07 has been conferred a protective effect [9, 13].

HSP is characterized by the deposition of IgA, mainly IgA1 isoform, immune complexes in the vessel walls of dermal capillaries, and in the renal mesangium. IgA-containing immune complexes and high blood levels of IgA in 50% of children can be observed during the acute phase of the illness. In addition, some studies have described the presence of IgA antineutrophil cytoplasmic antibodies (IgA-ANCA), IgA-rheumatoid factor (IgA-RF), or IgA-anti-cardiolipin antibodies (IgA-aCL) [11].

IgA is physiologically present in serum and mucosal secretions. Two IgA isoforms exist, IgA₁ and IgA₂, the former being the most prevalent (90%) in the circulation. In general, IgA₁ has a hinge region containing up to six O-linked glycan chains consisting of N-acetylgalactosamine (GalNAc), sialic acid, and galactose due to β 1,3-galactosyltransferase action [8, 10, 13]. This leads to the clearance of IgA₁ molecules through its interaction with the asialoglycoprotein receptor (ASGP-R) of the hepatocytes [10]. Nevertheless, reduced activity of β 1,3-galactosyltransferase, secondary to genetic predisposition, IL-6 production and/or infections, has been found in HSP patients. Consequently, aberrant

Updates on Childhood-Onset Systemic Lupus Erythematosus

Selma Cecilia Scheffler Mendoza¹, Francisco Eduardo Rivas-Larrauri¹ and Ana Luisa Rodríguez-Lozano^{1,*}

¹ Immunology Department, Instituto Nacional de Pediatría, Mexico City, Mexico

Abstract: Systemic Lupus Erythematosus (SLE) is a chronic, autoimmune, and multisystem disease. Childhood-onset SLE (cSLE) contributes up to 20% of all cases of SLE and refers to patients who develop the disease before their 18th anniversary.

Impressive discoveries in all aspects of the disease emerge every day; one of the most interesting is whether cSLE is a single or a group of diseases, with diverse physiopathologic processes but sharing a rough phenotype. Patients with early onset disease (<5 years), with associated infections and severe disease manifestations, should urge the possibility of monogenic SLE, which represents a small proportion of all cSLE cases, but often with a more complicated clinical course.

Despite its being considered a rare disease, the clinical outcomes could be devastating. Patients with cSLE had higher disease activity indexes than adults. Although the survival has improved, it also implies that patients remain a longer period under the effects of the disease.

Enormous advances in the understanding of the physiopathological processes are helping to better diagnose children with lupus; still, we are distant to have a perfectly fitted therapy for all our patients. The outstanding efforts of clinicians and researchers to find new therapeutic strategies are encouraging.

In this chapter, you will find a concise description of the novel advancements concerning the disease pathogenesis, classification, assessment of disease activity, treatment, and outcomes.

Keywords: Autoimmune disease, Classification criteria, Childhood-onset, Clinical manifestations, Cyclophosphamide, Disease activity, Damage, Epidemiology, Genetics, Glucocorticoids, Monogenic lupus, Mycophenolate mofetil, Outcome, Pathogenesis, Pediatric, Photoprotection, Systemic lupus erythematosus, Targeted immunotherapy.

* Corresponding author Ana Luisa Rodríguez-Lozano: Immunology Department, Instituto Nacional de Pediatría, Mexico City, México; Tel: +52 (55) 1084 - 0900; Ext. 1579, 1337; E-mail: anarlozano@yahoo.com.mx

INTRODUCTION

Systemic lupus erythematosus (SLE) is a complex, multisystem, chronic autoimmune disease [1] with the potential to involve any organ or system, with an unpredictable clinical course [2]. Characterized by the presence of numerous autoantibodies [3, 4], it commonly causes organ damage [5].

Childhood onset systemic lupus erythematosus (cSLE) is the preferred term to designate children who before their 18th birthday have met the classification criteria for systemic lupus erythematosus [6]. cSLE represents up to 20% of all patients with SLE [7]; other names as juvenile systemic lupus erythematosus, and pediatric systemic lupus erythematosus, are usually used in the literature.

Since the first cases were reported [8 - 13], impressive and continuous discoveries have been made in all aspects of the disease, one of the most exciting is whether cSLE is one disease or a group of diseases representing groups of patients with different physiopathologic processes, sharing several clinical manifestations and antibody profiles, that as a result, have allowed us to treat them more efficiently. There are many additional interesting aspects of the disease that will be reviewed in this chapter.

EPIDEMIOLOGY

cSLE is considered a rare disease, with higher frequency reported in Asians, African Americans, Hispanics, and Native Americans [14, 15]. The estimated incidence in England was 0.8 (0.5-1.2) per 100,000 children per year, but as mention previously, it varies depending on the ethnic origin. In Asia it was 5.6 (3.0-9.5) and in blacks 3.1 (0.6-9.1) while for whites was 0.4 (0.2-0.7) per 100,000 per year [16]. Australia has reported an annual incidence of 0.32 per 100,000 per year [17]. In the United States of America, the incidence was 2.2 per 100,000 Medicaid enrollees per year, while the prevalence was 9.73 per 100,000 [18]. More recently, an analysis of the online databank of the World Bank Group, taking into account 192 countries in 2017, estimated that there were over 200,000 children with cSLE, the majority concentrated in Asia and Africa, followed by the Americas, Europe, and Oceania with a prevalence of 113,176; 53,731; 24,315; 14,693 and 1,008; respectively [19]. Finally, in Korea, the prevalence was 5.35 per 100,000, and the incidence of 2.2 per 100,000 per year in patients between 5 and 18 years old. Interestingly, the authors noted an increase in the incidence and prevalence of girls age 14 and 15 years, observed in their change-point incidence graphics [20].

The median age at presentation is reported between 11 – 12 years, while the disease is very rare under the age of 5 years [15]. However, there is a tendency to

separate patients by the pubertal stage. Smith and cols [21] resume the findings of Abdwani *et al.* [22], Pluchinotta *et al.* [23], Descloux *et al.* [24], and Gomes *et al.* [25], and the details are depicted in Table 1.

Table 1. Number of cSLE patients by pubertal stage and gender distribution.

Author	Age Grouping			F:M
	Prepubertal	Peripubertal	Postpubertal	
-				-
Abdwani, N=103	39	29	35	83:20
Pluchinotta, N=53	13	11	29	38:15
Descloux, N=56	9	21	26	39:17
Gomes, N=847	39	395	413	726:121

There is a clear predominance of girls compared with boys; this tendency seems to increase along with age. In the prepubertal stage, it is about 2 girls for every boy affected (2:1), only Gomes *et al.* reported 4:1. On the peripubertal stage, the sex ratio is more variable, from 2:1 to 6:1, and for the postpubertal stage, it is from 3:1 to 11:1.

The predominance of females in autoimmune diseases, particularly in patients with lupus, does not totally elucidate; however, there is information regarding the role of sex hormones. The estrogen affects all cells of the immune system, resulting in enhancing INF-gamma and antibody production, and together with prolactin, may be implicated in cell survival [26 - 28].

GENETIC AND PATHOGENESIS

Systemic lupus erythematosus is considered a disease resulting from multiple interactions of factors [29]. Familial aggregation is frequent in patients with cSLE [30] who have more relatives with autoimmune diseases, particularly SLE and thyroid disease, than those without lupus [31]. Previous studies in twins indicate a large concordance between monozygotic twins, although it seems that this concordance is lower [32]. Some authors described 15% of SLE heritability. It shows not only the importance of the genetic basis of the disease [33 - 37] but many other factors involved as the epigenetic [38 - 43], ambient, diet, and infections [44 - 46], among many others.

In a recent and comprehensive review of the genetic etiology of SLE, the authors state: *“It was previously thought that the relevant genetic variants and the causal molecular pathway involved in lupus were associated with distinct clinical presentations. This simplification greatly underestimated the biological complexity of this disease. Mutations within the same gene and identical gene*

Updates on Severe Combined Immunodeficiency

Fausto Cossu^{1,*}

¹ Pediatric Clinic of University, “Antonio Cao” Hospital, Cagliari, Sardinia, Italy

Abstract: Mutations in any one of several genes essential for T lymphocyte development and function cause human Severe Combined Immunodeficiency (SCID), a heterogeneous group of monogenic inborn errors of immunity.

Newborns with SCID acquire multiple, persistent, and severe viral, bacterial, and fungal infections shortly after birth and rarely reach their first birthday. SCID is a pediatric emergency: with prompt diagnosis and treatment, essentially every baby with SCID could be cured by hematopoietic stem cell transplantation or gene therapy.

Most SCID newborns appear normal and healthy at birth, but SCID is always a prenatal disorder of the development of T lymphocytes, and it is already present at birth. Therefore, SCID is detected by newborn screening through measurement of TRECs (T cell receptor excision circles), which counts naïve T lymphocytes, already absent or markedly reduced.

The vast majority of newborns worldwide are not yet screened for SCID. The diagnostic approach and the ‘natural history’ of affected infants and their families are now completely different depending on whether or not neonatal screening for SCID is available, apart from the availability/unavailability of SCID therapies (hematopoietic stem cell transplantation, *etc.*).

Keywords: B-cell, Bubble boy, Gene therapy, Genetics, Genotype, Hematopoietic stem cell transplantation, Immunodeficiency, Leaky mutation, Lymphopenia, Maternal engraftment, Newborn screening, NK-cell, Null mutation, Omenn syndrome, Phenotype, SCID, T-cell, Thymus, TRECs, Viral vector.

INTRODUCTION

Mutations in any one of several genes essential for T lymphocyte development and function cause human SCID (Severe Combined Immunodeficiency), a heterogeneous group of monogenic inborn errors of immunity with an overall incidence of about 1 in 50,000 to 90,000 newborns [1 - 4]. The incidence is rema-

* Corresponding author Fausto Cossu: Pediatric Clinic of University, “Antonio Cao” Hospital, Via Jenner sn, 09121 Cagliari, Sardinia, Italy; Tel: (+39) 070 52965660; E-mail: fausto.cossu@unica.it

rkably higher in many ethnic groups due to the founder effect and common consanguineous marriage (AR, autosomal-recessive, SCID) [5 - 7].

Usually, “null” mutations of these genes with the absence of residual gene/protein function cause Typical SCID, while “non-null” (“hypomorphic”, “leaky”) mutations allowing some residual functions are associated with Atypical SCID.

“Typical/Atypical” refers to the clinical and immunological phenotype, “null/non-null, hypomorphic, leaky” to the molecular findings.

In 2008, Wisconsin, Massachusetts, and the Navajo Nation (USA) became the first states in the world to screen all newborns for SCID by measurement of T cell receptor excision circles, TRECs [8], and as of December 2018, all 50 states in the USA (plus the District of Columbia, Guam and Puerto Rico) performed universal Newborn Screening (NBS) for SCID. Similar NBS have been implemented in Taiwan, Israel, Iceland, New Zealand, Norway, Sweden, Switzerland, Lebanon, Germany, and some regions of Canada, Finland, Spain (Catalonia), Italy (Tuscany). Pilot programs have been completed or are ongoing in Iran, Brazil, Netherlands, Saudi Arabia, UK, France, and other countries [9, 10].

The diagnostic approach to SCID and the ‘natural history’ of SCID infants, their families, and their clinicians are now completely different in these two conditions: NO NBS for SCID *versus* YES NBS for SCID [11, 12].

The vast majority of newborns worldwide are not yet screened for SCID. This happens both in developing countries, where also hematopoietic stem cell transplantation (HSCT) is very rarely available [13], and for example, in most of Europe, where often SCID NBS is absent but, instead, whole-exome sequencing (WES) may be possible.

NO NEWBORN SCREENING FOR SCID

In the absence of NBS, the initial clinical manifestations of SCID are most frequently observed in the first few months of life, and the median age at diagnosis is 4-7 months; so, apart from families with a recognized positive history of SCID (<20 percent of cases), ‘delayed diagnosis, harmful administration of contra-indicated live vaccines, delay in clinical management and poor outcome are still too frequent’ [6].

To achieve a timely clinical/genetic diagnosis, it is essential to know and remember many aspects of SCID [3].

Children with SCID have absent or very low naïve CD3 T cells, do not produce T lymphocytes or, however, functional T lymphocytes, and acquire multiple, persistent and severe viral, bacterial and fungal infections shortly after birth.

Fever, cough, persistent thrush and mucocutaneous candidiasis, upper airway infections, bronchiolitis, pneumonia, skin infections, diarrhoea, meningitis, sepsis, systemic viral infections, disseminated fungal infection, *etc.* affect infants by common and opportunistic pathogens such as cytomegalovirus (CMV), Epstein-Barr virus (EBV), adenovirus, respiratory syncytial virus (RSV), herpes simplex virus (HSV), varicella zoster virus (VZV), rotavirus, norovirus, influenza and parainfluenza viruses, *Staphylococcus spp.*, *Streptococcus spp.*, *Pseudomonas spp.*, *Escherichia coli spp.*, other Gram- *spp.*, *Candida spp.*, *Pneumocystis jirovecii*, *Aspergillus spp.*, *etc* [14, 15].

Children fail to thrive and rarely reach their first birthday.

In SCID (or suspected SCID) infants, it is mandatory that all transfusions involve irradiated and preferably WBC-filtered blood products to avoid the transfusion of functional donor lymphocytes, which would certainly cause life-threatening Graft *versus* Host Disease (GvHD). In fact, this precaution should be used in all newborns as a general rule.

SCID is a pediatric emergency [16] with prompt diagnosis and treatment, and before acquiring an infection, including infections from “live” vaccines, *e.g.*, *Bacille Calmette-Guérin* (BCG), or rotavirus [17, 18], essentially every baby with SCID could be cured by HSCT or gene therapy (GT).

Most newborns with SCID appear normal and healthy at birth, but cutaneous signs similar to GvHD from engraftment of transplacentally derived maternal T lymphocytes are sometimes present.

Instead, low birth length and weight, microcephaly, dysmorphic facies, metaphyseal chondrodysplasia or other skeletal abnormalities, alopecia, congenital heart disease, *etc.* are nonimmunological manifestations of the less frequent forms of SCID in which cell types and organs other than lymphocytes and lymphoid organs are also affected by their genetic mutations (“syndromic SCIDs”).

However, even if most newborns with SCID appear normal and healthy, SCID is always a prenatal disorder of the development of T lymphocytes, and it is already present at birth.

Updates on PFAPA- Periodic Fever, Aphthous Stomatitis, Pharyngitis, and Cervical Adenitis Syndrome

Beata Wolska-Kuśnierz^{1,*} and Bożena Mikołuc²

¹ Immunology Department, Children's Memorial Health Institute, Av. Dzieci Polskich 20, 04-730 Warsaw, Poland

² Department of Pediatrics, Rheumatology, Immunology and Metabolic Bone Diseases, Medical University of Białystok, Waszyngtona 17 Str., 15-274 Białystok, Poland

Abstract: PFAPA- Periodic Fever, Aphthous Stomatitis, Pharyngitis, and Cervical Adenitis syndrome are the most common autoinflammatory syndromes in children. In this chapter, the characteristic manifestation and clinical criteria of PFAPA, which remain the basis of diagnosis, are presented. The therapeutic options and prognosis are discussed in detail.

Keywords: Adenitis, Anakinra, Aphthous stomatitis, Autoinflammation, Colchicine, Interleukin-1, Interleukin-1 blockers, Marshall syndrome, Periodic fevers, PFAPA, Pharyngitis, Tonsillectomy, Tonsillotomy.

INTRODUCTION

PFAPA syndrome, firstly described in 1987 by Marshall et al., is the most common among the auto-inflammatory diseases of childhood [1, 2]. The name is derived from the first letters of the main clinical symptoms: **P**eriodic **F**ever, **A**phthous stomatitis, **P**haryngitis, and **C**ervical **A**denitis. Despite the passage of more than 30 years, knowledge about the pathogenesis of the syndrome remains still limited. We currently include PFAPA in the group of autoinflammatory diseases caused by polygenic or complex inheritance of variants in many genes in association with environmental factors. There appears to be no predilection for a particular ethnic or racial group, although male predominance for a particular ethnic group was established [3 - 5]. The concept of auto-inflammation was proposed by Kastner in 1999, and it included genetically determined disorders of

* **Corresponding author Beata Wolska-Kuśnierz:** Immunology Department, Children's Memorial Health Institute, Av. Dzieci Polskich 20, 04-730 Warsaw, Poland; Fax: +48 11 815 18 39; Email: b.wolska-kusnierz@ipczd.pl

the innate immune system, manifested by recurrent fever with a different spectrum of accompanying symptoms. Auto-inflammatory diseases, in contrast to autoimmune disorders, are characterized by seemingly unprovoked, pathological activation of the innate immune system in the absence of autoantibodies or autoreactive T cells [6]. This new group of diseases has been dynamically developing in the last two decades and already covers several dozen disease entities, the number of which is systematically growing every year.

ETIOLOGY

PFAPA syndrome has no established genetic basis, may occur sporadically, but quite often, the family history of patients with recurrent fever, tonsillitis, recurrent streptococcal pharyngitis, tonsillectomy, and recurrent aphthous ulcers indicates the possibility of a genetic predisposition, perhaps of a multigenic nature. Although knowledge about PFAPA pathomechanism is still a puzzle, research indicates impaired functioning of the innate immune system. Similarly, as in other classical auto-inflammatory syndromes, the role of inflammasome over-activation and interleukin-1(IL-1) secretion during episodes of fever is underlined. In the course of relapses, IFN-gamma, IFN-gamma induced proteins (IP 10 also called CXCL10 for chemokine, CXC motif, ligand 10) and proteins induced by gamma interferon (MIG or CXCL9), G-CSF, TNF-alpha, and other proinflammatory cytokines (IL-1 beta, IL-6, IL-18) are elevated [7, 8]. Monocytes isolated from patients during fever secrete greater amounts of IL-1 β after stimulation with LPS (lipopolysaccharides) compared to cells collected in the asymptomatic period and from healthy people [8 - 10]. Relapses of fever are accompanied by an increase in the number of neutrophils and monocytes and a decrease in the number of eosinophils and lymphocytes. Probably unknown environmental factors constitute a trigger mechanism to over-run the inflammatory response with activation of the complement and interleukins IL-1 β /IL-18, with induction of Th1 response, followed by inhibition of the activated T lymphocytes in peripheral tissues. Long et al. hypothesized that the periodicity of the PFAPA syndrome derives from intermittent expression or suppression of antigens or epitopes of infectious agents or an alteration in the nature or kinetics of immunological response [11]. In spite of its strong familial clustering, the genetic basis and inheritance pattern of PFAPA are still unknown. Results of a relatively large cohort indicate that PFAPA syndrome is unlikely to be a monogenic condition [12]. Some variants of unknown significance in known auto-inflammatory-causing genes have been reported in PFAPA syndrome at higher frequency (also known as burden of variants). Best known examples include p.R121Q(R92Q) in TNF receptor superfamily member 1A (*TNFRSF1A*), heterozygosis or polymorphisms in the familial Mediterranean fever gene *MEFV*, mevalonate kinase *MVK* gene, or NLR family pyrin domain-containing 3 (*NLRP3*) [13].

In the literature, we found information about genetic similarities among PFAPA, recurrent aphthous stomatitis, and Behçet's disease. PFAPA shares risk loci at *IL12A*, *STAT4*, *IL10*, and *CCR1-CCR3* with Behçet's disease and recurrent aphthous stomatitis, defining a family of Behçet's spectrum disorders (BSDs). Manthiram and colleagues confirmed new class I and II *HLA* associations for PFAPA distinct from Behçet's disease and recurrent aphthous stomatitis, but HLA-B15 was identified as a risk allele for all of the BSDs [14]. All data suggest that PFAPA results from oligogenic or complex inheritance of variants in multiple disease genes and/or non-genetic factors. Because tonsillectomy is curative in most patients, there is a hypothesis that the palatine tonsils are the primary site of immune dysregulation in children with PFAPA. Tonsils of adult- and pediatric-onset in the asymptomatic PFAPA phase share unique histological features: smaller germinal center areas with a lower percentage of B lymphocytes, a higher percentage of CD8+ cytotoxic T lymphocytes and naïve T cells, and a lower percentage of CD4+ T cells with high expression of the inhibitory molecule PD-1 (programmed cell death 1) in germinal centers compared with controls [15 - 17]. In addition, high expression of T cell chemokines and proinflammatory cytokines in tonsils from patients with PFAPA was found [18].

CLINICAL MANIFESTATIONS

PFAPA is characterized by sudden onset of stereotypical episodes of fever, which persists for 3-6 days, resolves spontaneously, and regularly reoccurs every three to eight weeks; the average is approximately four weeks, alongside at least one of three main symptoms: aphthous stomatitis, cervical adenitis, and pharyngitis. It is an early-onset disease usually starting before the age of 5 years in 90% of patients [19]. The age of fever onset of adult patients with PFAPA is between 20 and 33 years of age. Fever episodes begin abruptly, and a temperature range from 38.5 to 41°C for two to seven days and then abruptly fall to normal. Episodes rarely last for more than seven days. Thus, prolonged fever episodes should prompt consideration of other diagnoses. It is important to confirm that the symptoms with each episode are nearly identical. There is male predominance but no predilection for a particular ethnic group [3]. However, an increasing number of adults with PFAPA have been diagnosed in recent years [4, 5]. Aphthous stomatitis, usually on the inner lips or buccal mucosa, occasionally in the posterior pharynx, is present in about 40-70% of children reported with PFAPA. Patients have had few to several non-clustered, small (<5 mm), shallow ulcers that heal over 5 to 10 days. In opposite to the ulcers of Behçet syndrome, aphthous ulcers in PFAPA are not as large or painful nor do they scar. Prodromal symptoms such as malaise, irritability, and fatigue may manifest during the preceding days. Typically, along with a fever, tonsillitis is observed. Tonsils are red inflammatory exudates with different morphology (photo 1 and 2). Their appearance may

Updates on Pediatric Hepatoblastoma

Consolato M. Sergi^{1,2,*}

¹ Division of Anatomic Pathology, Children's Hospital of Eastern Ontario, University of Ottawa, ON, Canada

² Department of Laboratory Medicine and Pathology, Stollery Children's Hospital, University of Alberta, Edmonton, AB, Canada

Abstract: The developing human liver is embryologically central in embryogenesis. It plays a significant role as a hematopoietic and endocrine organ. During the development, hepatocytes change their phenotype. They vary from blueish cells to cells with an eosinophilic nuance and decreased nucleus to cytoplasm ratio. Apart from congenital abnormalities of this organ and inflammatory conditions that can populate medical charts in childhood and youth, the liver's neoplastic transformation in childhood and adolescence is a rare event. In children younger than three years, the liver's most dramatic neoplasm is represented by the occurrence of hepatoblastoma. It is an embryologic tumor. It retains the suffix "blastoma," similar to neuroblastoma as any other embryologic tumor. Hepatoblastoma originates presumably from the primitive embryo-fetal progenitors. In this chapter, we update our knowledge of this pediatric tumor, specifically the pathology and the treatment.

Keywords: Advocacy, Anatomy, Beckwith Wiedemann syndrome, Beta-Catenin, Child, Embryology, Familial adenomatous polyposis coli, Genetics, Hepatoblastoma, Liver, Microscopy, Neoplasm, Pathology, Quality Assurance, Radiology, Simpson–Golabi–Behmel syndrome, Sotos syndrome, Trisomy 18 syndrome, Tumor, World Health Organization.

INTRODUCTION

Hepatoblastoma is one of the most dramatic neoplasm of the first three years of life. It is an embryologic tumor of the liver showing several histologic patterns ranging from small round blue cell type morphology to a phenotype. It is quite similar to normal hepatocytes. The developing human liver is embryologically central in embryogenesis. It plays a major role as a hematopoietic and endocrine organ. In terms of development, hepatocytes change their phenotype. They vary

* Corresponding author **Consolato M. Sergi:** Division of Anatomical Pathology, Children's Hospital of Eastern Ontario (CHEO), University of Ottawa 401 Smyth Road Ottawa, ON K1H 8L1 Canada; Tel: 613-737-7600 x 2427; Fax: 613-738-4837; E-mail: csergi@cheo.on.ca

from blueish cells to cells with an eosinophilic nuance and decreased or variable nucleus to cytoplasm ratio. Apart from congenital abnormalities of this organ and inflammatory conditions that can populate medical charts in childhood and youth, the liver's neoplastic transformation in childhood and adolescence is a rare event. About two-thirds of liver neoplasms occurring in the pediatric age are malignant. Nearly the same ratio is either hepatoblastoma or hepatocellular carcinoma. The former occurs mainly in the first triennium and the latter in children aged four or older [1 - 4]. This update will highlight the impressive increase in the overall survival of patients suffering from hepatoblastoma.

TUMOR CELL OF ORIGIN

In children younger than three years, the liver's most dramatic neoplasm is represented by the occurrence of hepatoblastoma. This tumor is an embryologic neoplasm. It retains the suffix "blastoma" similar to neuroblastoma or nephroblastoma (Wilms' tumor) that characterizes most of the embryologic tumors [5]. Hepatoblastoma does not originate from primary hepatoblasts, but it seems that less differentiated cells are the culprit in this neoplastic event. The human fetal liver multipotent progenitor cells (hFLMPCs), which are poorly differentiated, can convert into various tissues. These tissues include hepatocytes, bone, fat, or bile ducts. The differences identified in multiple histological patterns of hepatoblastoma would explain its variety. In fact, up to 40% of tumor samples contain both epithelial and mesenchymal components [6]. The beta-catenin pathway is crucial for developing a variety of organs in the human body [7]. It is tightly linked to the Wnt signaling pathway. Wnt is a hybrid name created from the words Wingless and Int-1. In cell physiology, Wnt signaling use either cell-cell (paracrine) or same-cell communication (autocrine). It is so powerful that it is highly evolutionarily conserved in animals, ranging from fruit flies to humans. The canonical Wnt-beta-catenin pathway is a complex, evolutionarily conserved mechanism that regulates essential processes in both physiology and pathology. Among the several aspects, it has been demonstrated that Wnt-beta-catenin signalling controls embryogenesis, maturation and zonation [7]. In the healthy liver of a mature organism, the Wnt-beta-catenin pathway is mostly inactive. However, this pathway becomes active (or better re-active) during cell renewal and/or regenerative processes. These processes include several diseases, pre-malignant abnormalities, and neoplasms. In both hepatocellular carcinoma (HCC) and cholangiocarcinoma (CCA), which are the two most prevalent primary liver tumors in adults, Wnt-beta-catenin signaling is often hyperactivated. It is critical in promoting tumor cell growth and dissemination. Activating mutations have been found in a considerable percentage of both HCC and CCA, although HCC is largely dominant on CCA [8, 9]. Similarly, hepatoblastoma researchers discover Wnt-beta-catenin activation with beta-catenin mutations in most of these

embryologic tumors [10]. In a murine transgenic model using floxed beta-catenin (exons 2-6), and mice intercrossed with Albumin-Cre recombinase, Tan *et al.* found beta-catenin redundancy in the liver [11]. Lack of beta-catenin delays liver regeneration, but it does occur in a suboptimal way. In the case of 2/3 of partial hepatectomy, the *Ctnnb1*(loxp/loxp)-Alb-Cre(+/-) mice were passive in the first three days, but they showed an increase of hepatocyte proliferation after this time [11]. Beta-catenin has recently been demonstrated to cooperate with Yap signaling in the majority of hepatoblastomas [12 - 15].

CLINICAL PRESENTATION

Hepatoblastoma can occur sporadically or in the setting of familial cancer syndromes. These syndromes are Beckwith Wiedemann syndrome, Simpson–Golabi–Behmel syndrome, Sotos syndrome, familial adenomatous polyposis (FAP) coli, and trisomy 18 syndrome. Hepatoblastoma is more often seen in premature babies, with about 60% of a Japanese series affecting infants with birth weight less than 1000g [16]. In about 90% of patients with hepatoblastoma, there is an increase of alpha-fetoprotein (AFP), which may be puzzling because the premature liver contains and secretes a substantial amount of AFP. Other than nonspecific symptoms, including not gain of weight or weight loss associated with loss of appetite or anorexia, the abdominal mass can be discovered by ultrasound examination. It is a hyperechoic solid mass, which can be better delineated by computed tomography (CT) scan. CT scan will highlight the hepatoblastoma as a hypoattenuating mass with a clear boundary between the tumor and surrounding liver tissue.

PATHOLOGY

Hepatoblastoma can be essentially divided into two main categories, which include epithelial and epithelial/mesenchymal or mixed type. A few subtypes have been recognized in the epithelial category. They comprise fetal, embryonal, combined fetal and embryonal, macrotrabecular, and small cell types. The presence of mixed type is characterized by some mesenchymal tissue elements, such as cartilage or osteoid in addition to the epithelial component. In 6-8 weeks of gestation, the human liver shows basophilic cells with a high nucleus to cytoplasm ratio. This feature is seen in embryonal hepatoblastoma (EHB), which is the most often met histology pattern. These cells are approximately 10-15 micrometers in diameter and mostly round. The embryonal hepatoblast joins neighboring cells and grows in sheets. They form acinar (2D) or tubular (3D) structures around a central lumen. The more mature liver cells or fetal hepatoblasts acquire some features similar to more mature hepatocytes. These cells are relatively bigger than embryonal hepatoblasts. The nucleus to cytoplasm

Updates on Mitochondrial Disorders in Children

Ramesh Bhat Y^{1,*}

¹ Department of Paediatrics, Kasturba Medical College, Manipal Academy of Higher Education University, Manipal-576104, Karnataka, India

Abstract: Each human cell contains a few hundred mitochondria that are essential for aerobic energy metabolism. Among many fundamental metabolic pathways in mitochondria, the oxidative phosphorylation (OXPHOS) or the respiratory chain (RC) represents the final stage in oxidative metabolism. RC is under the dual control of the mitochondrial genome (mtDNA) and the nuclear genome (nDNA). The proper assembly and functioning of the RC involve many steps. The genetic defects in mtDNA, nDNA, and related functions of mitochondria affect the functioning of RC resulting in insufficient energy production and organ dysfunction.

Mitochondrial disorders are increasingly recognized. The clinical manifestations vary widely, causing a significant diagnostic challenge. Manifestations range from lesions of single tissue or structure to widespread lesions, including myopathies, encephalomyopathies, cardiopathies, neurogastrointestinal form, psychiatric symptoms, or complex multisystem syndromes. Coenzyme Q10 deficiency may present with isolated proximal muscle weakness. Leigh syndrome and MELAS are the most common clinical multisystem syndromes. The age at onset ranges from neonatal to adult life. The mortality remains high, and the median survival for early onset severe disease is 12 years. Initial evaluations include blood transaminases, lactate-to-pyruvate ratio, amino acids, acylcarnitine profile, creatine kinase, and organic acids. Genetic tests are needed for confirmation.

Treatment depends on the specific mitochondrial disorder and its severity. In an acute presentation, an infection should be sought and treated promptly. Coenzyme Q10, thiamine, riboflavin, lipoic acid, L-carnitine, Creatine, and L-Arginine are found to be beneficial. Although there are no cures, treatments reduce symptoms or slow the decline in health.

Keywords: Arginine, Carnitine, Coenzyme Q, Encephalopathy, Energy, Lactic acidosis, Leigh syndrome, Magnetic resonance, MELAS, Mitochondrial disorders, Mitochondrial depletion, Mitochondrial membrane, mtDNA, Muscle

* Corresponding author Ramesh Bhat Y: Department of Paediatrics, Kasturba Medical College, Manipal Academy of Higher Education University, Manipal- 576104, Karnataka, India; Tel: +91 9448296564; Fax: +91820 2571927; E-mail: docrameshbhat@yahoo.co.in

biopsy, Myopathy, nDNA, Neuropathy, OXPHOS, Ragged-red fibers, Respiratory chain, Riboflavin, Stroke, Thiamine.

INTRODUCTION

Mitochondria are the cellular organelles responsible for oxidative phosphorylation (OXPHOS) and the production of energy in the form of adenosine triphosphate (ATP). The energy production occurs in the mitochondrial respiratory chain (RC). Mitochondria also perform other tasks such as combating the production of reactive oxygen species and initiating apoptosis. They also house a variety of metabolic reactions such as pyruvate oxidation and metabolism of amino acids, fatty acids, and steroids. The five complexes, complexes I to V, of the mitochondrial RC contain approximately 80 proteins, of which 13 are encoded by mtDNA and the remaining proteins by the nDNA. The nDNA ultimately controls the proper assembly and functioning of the RC involving many steps. The defects of mtDNA and nDNA result in two important categories of mitochondrial disorders. Mutations in mtDNA such as tRNA or rRNA gene mutations and rearrangements may impair the total mitochondrial protein synthesis or may affect one of the 13 respiratory chain subunits encoded by mtDNA [1 - 4].

Mitochondrial disorders are inherited disorders of energy metabolism caused by impairment of the OXPHOS system. Defects in any of the mitochondrial functions can lead to primary mitochondrial disorders. Mitochondrial disorders present with a wide range of clinical expressions. Multisystem involvement is the hallmark of the disorder and is quite disabling. The organ systems that mostly rely on aerobic metabolism are preferentially affected. In patients with predominantly multisystem disorder, there is a variable combination of central and/or peripheral nervous system involvement, ophthalmologic abnormalities, sensorineural hearing loss, gastrointestinal symptoms, cardiac, hepatic and renal disorder, endocrine dysfunction, and short stature. Central nervous system involvement is also common. Single structure involvement may be seen in Leber's hereditary optic neuropathy (LHON) and maternally inherited non-syndromic deafness. Mitochondrial myopathy refers to skeletal muscle involvement either alone or with central nervous system disorder. The major mitochondrial depletion syndromes (MDS) include myopathic (mutations in TK2, RRM2B, and AGK), encephalomyopathic (mutations in SUCLA2, SUCLG1, and RRM2B), hepatocerebral (mutations in GDUOK, MPV17, POLG, and C10ORF2), and/or neurogastrointestinal (TYMP mutations) types. The age of onset of mitochondrial disorders varies from neonatal to adult life. Neonates, too, have severe manifestations. The diagnosis, lab investigation, and treatment depend on the clinical type and severity of the disorder [1, 2, 5, 6].

EPIDEMIOLOGY

The current prevalence of childhood-onset mitochondrial disorders has been predicted to range from 5 to 15 cases per 10,000. Primary genetic mitochondrial disorders are among the most common inborn errors of metabolism, with a minimum incidence of 1: 5,000. The point prevalence in children younger than age 16 years is estimated to be 1 in 21,000. A population-based study from western Sweden from 1984 until 1999 found that the incidence of mitochondrial encephalomyopathies in preschool aged children was 1 in 11,000 [7]. The incidence and prevalence of mitochondrial myopathies are slightly less than those reported for mitochondrial encephalomyopathies. The prevalence of mtDNA point mutations was greater than 1 in 200 individuals among newborns. Due to variable heteroplasmy, some of these mutations will never be clinically expressed. An Australian study estimated the minimal birth prevalence of primary mitochondrial disorders to be 6.2 cases per 100,000 births [8]. The mortality of these disorders in childhood is high, and many children are expected to survive till 3 to 9 years of age. The median survival for children with infantile onset is said to be 12 years.

PATHOGENESIS

Mitochondria, the organelles present in each human cell, carry out many fundamental metabolic pathways, including the respiratory chain, fatty acid β -oxidation, and the tricarboxylic acid (TCA) cycle. The much essential aerobic energy metabolism takes place in the mitochondria. The oxidative phosphorylation or the respiratory chain represents the final stage in oxidative metabolism. The respiratory chain is located in the inner mitochondrial membrane and is composed of five intramembrane complexes and two mobile electron carriers, coenzyme Q10 (CoQ10) and cytochrome c. The five multi-subunit enzyme complexes include complex I, or NADH ubiquinone reductase, which re-oxidizes NADH derived from the oxidation of fatty acids, amino acids, and pyruvate; complex II, or succinate-ubiquinone oxidoreductase, which oxidizes FADH₂ derived from the TCA cycle; complex III, or ubiquinol-ferricytochrome-c oxidoreductase; complex IV or cytochrome c oxidase, and complex V, or ATP synthase. Complexes I, III, and IV pump protons from the mitochondrial matrix into the intermembrane space and the energy which this creates is harnessed by ATP synthase for the production of ATP from ADP. Both the mitochondrial and nuclear genes contribute proteins to the OXPHOS pathway. Human mtDNA is a 16.569-kb circular, double-stranded molecule, which contains 37 genes: 2 rRNA genes, 22 tRNA genes, and 13 structural genes encoding the respiratory chain subunits. About 13 proteins of RC are encoded by mtDNA, and the remaining proteins by the nDNA. Complex II, coenzyme Q, and cytochrome c are exclusively encoded by nDNA [3, 4].

SUBJECT INDEX

A

- Abdominal 13, 14, 15, 46, 87, 93, 290, 310, 311, 315, 317, 318, 342, 431, 432
 angina 46
 cramping 290
 pain 13, 14, 15, 87, 93, 310, 311, 315, 317, 318, 342, 431, 432
- Abnormalities 26, 101, 152, 156, 157, 172, 190, 196, 202, 204, 206, 211, 214, 216, 218, 235, 262, 393, 397, 437, 438, 453, 462, 463, 464, 469
 chromosomal 214
 congenital 26, 437, 438
 coronary artery 101
 cortical migration 202
 genetic 262
 liver function 196
 lung 393
 metabolic 172, 190
 neurological 397
 ophthalmologic 453
- Absolute lymphocyte count (ALC) 336, 337, 378, 379, 405, 406, 414
- Acalculous cholecystitis 99, 101
- Acanthosis nigricans 82
- ACE inhibitors 91
- Acids 205, 216, 217, 218, 223, 262, 263, 285, 312, 346, 353, 354, 387, 393, 397, 452, 453, 454, 465, 466, 471, 474, 475, 477
 amino 387, 393, 452, 453, 454, 465, 466
 deoxyribonucleic 346
 dicarboxylic 466
 folic 223, 475
 homovanillic 205
 lipoic 452, 474, 477
 mycophenolic 353, 354
 pyrrolidine carboxylic 262
 sialic 312
 tricarboxylic 454
 uric 397, 466
 urocanic 262
 valproic 216, 217, 218, 471
 peptide-nucleic 477
 sphingomyelinase 262, 263
- Activated macrophages 126
- Acute 10, 11, 17, 25, 43, 231, 233, 234, 235, 236, 239, 241, 245, 246, 247, 249, 251, 252
 disseminated encephalomyelitis (ADEM) 231, 233, 234, 235, 236, 239, 241, 245, 246, 247, 249, 251, 252
 pancreatitis (AP) 17
 post streptococcal glomerulonephritis (APSGN) 25
 recurrent pancreatitis (ARP) 17
 respiratory distress syndrome (ARDS) 10
 rheumatic fever (ARF) 11, 43
- Addison's disease 19
- Adenoidectomy 433
- Adenosine deaminase 107
- Adenylate kinases (AKs) 392
- Agammaglobulinemia 378, 384, 386
- Agents 66, 84, 105, 113, 239, 240, 248, 286, 290, 353, 468, 470, 472, 474
 antimalarial 353
 effective topical antipruritic 286
 immunomodulatory 239
 multiple antihypertensive 113
- Aicardi-Goutières syndrome (AGS) 328, 330, 357
- Alanine amino-transferase 47
- Albumin-Cre recombinase 439
- Aleukocytosis 392
- Alexander's disease 250
- Alkaline phosphatase 47
- Allergic rhinitis 27, 92, 146, 260, 266, 272, 277
 and adenotonsillar hypertrophy 146
- Alloantigens 403, 406
 non-inherited maternal 403
- Alveolar 93, 148
 bone condensation 148
 hemorrhage 93

Subject Index

Aminoaciduria 458, 461
Aminoglycosides 471
Amyloidosis 44, 61, 433
ANCA associated vasculitis (AAV) 46, 49,
86, 92, 95, 106, 107, 476
Anemia 3, 13, 47, 58, 63, 64, 68, 81, 101, 103,
107, 456, 461, 465
in rheumatologic conditions 47
pediatric 13
sideroblastic 456, 461, 465
Anesthesia 243, 444, 469
Angelman syndrome 215
Angiotensin converting enzyme (ACE) 76
Ankyloglossia 151
Ankylosing spondylitis 27, 57
Anomalies 153, 327, 393, 411
neurological 393
orofacial 153
Anorectal malformation 16
Anti-alanyl-tRNA synthetase 81
Antibodies 52, 81, 85, 233, 340, 341
antiphospholipid 52, 340, 341
anti-polymyositis scleroderma 81
anti-synthetase 81, 85
myelin oligodendrocyte glycoprotein 233
Anti-IgE monoclonal antibody 293
Anti-infective activity 410
Anti-inflammatory 105, 286, 287
activity 286
agents 105, 287
Antimicrobial peptide therapies 291
Antioxidant enzymes 476
Antiphospholipid syndrome (APS) 40, 49, 52,
114, 115, 116, 117, 119, 120, 341, 359
Antipruritic therapy 286
Anti-RNA polymerase 75
Anti-topoisomerase 75
Antitubercular therapy 113
Apoptosis 328, 331, 352, 397, 472
Arteriosclerosis 112
Arteriovenous malformation 193
Arthritis 19, 27, 40, 42, 43, 44, 45, 48, 49, 52,
53, 54, 55, 57, 58, 59, 60, 74, 87, 93,
289, 341, 346
enthesitis-related 49, 57

Updates on Pediatric Health and Diseases 481

infectious 19
juvenile idiopathic 19, 27, 40, 43, 52
psoriatic 55
rheumatoid 54, 289
septic 19, 42, 43
systemic 60
Aspiration 10, 80, 84, 125
pneumonia 125
Asthma 8, 10, 27, 260, 266, 272, 277, 278,
294
Astrocytoma 250
Asymmetric paralysis 243
Atherogenesis 171, 175
Atherosclerosis 96
ATP synthase 454
Atrial septal defect (ASD) 12
Atrioventricular canal defect 12
Atrophy 67, 71, 149, 198
parenchymal 198
Autoantibodies 18, 50, 65, 81, 313, 325, 330,
332, 351, 357, 429
anti-tRNA synthetase 81
myositis-associated 81
Autoimmune 7, 8, 13, 18, 24, 27, 43, 50, 51,
61, 67, 71, 72, 86, 87, 114, 236, 246,
324, 326, 332, 392, 429, 453, 473
demyelinating disorder 236
diseases 18, 24, 27, 43, 50, 67, 71, 72, 86,
87, 324, 326, 332
disorders 7, 8, 18, 27, 51, 61, 114, 246, 429
thrombocytopenic purpura (ATP) 13, 392,
453, 473
thyroiditis 18
Auto-inflammatory syndromes 432
Automatic internal cardiac defibrillators
(AICD) 475
Autosomal recessive (AR) 221, 222, 223, 327,
328, 330, 331, 383, 385, 397, 398, 458,
459
multisystemic syndrome 459

B

Bacille Calmette-Guérin (BCG) 377, 408

- Barré 388, 460, 461, 475
 syndrome 388
 syndrome 460, 461, 475
 Behçet's 121, 430, 432
 disease 121, 430, 432
 spectrum disorders (BSDs) 430
 Behmel syndrome 437, 439
 Benign familial infantile 213, 222
 epilepsy (BFIE) 222
 Seizures (BFIS) 213
 Beta-catenin redundancy 439
 Bilateral bulbar conjunctival injection 102
 Bladder dysfunction 237
 Blau syndrome 121, 122, 123
 Bleeding disorders 3
 Blood 48, 452
 transaminases 452
 urea 48
 Blood pressure 66, 110, 173, 177
 diastolic 173, 177
 systolic 173
 Bowel dysfunction 234
 Bronchopulmonary dysplasia (BPD) 10
 Bruton's X-linked agammaglobulinemia 403
- C**
- Calcaneal apophysitis 21
Candida albicans 153, 154
 Candidiasis 153, 389
 Cardiac myocarditis 46
 Cardiomyopathies 11
 Cardiomyopathy 46, 68, 114, 348, 446, 458, 462, 465, 475
 Cardiopulmonary 74
 Cardiorespiratory 177, 337
 Cardiovascular diseases 11, 172, 272, 294
 Cartilage-hair hypoplasia (CHH) 399
 Cellulitis 155
 Central nervous system (CNS) 64, 65, 67, 190, 231, 232, 236, 237, 238, 241, 247, 248, 316, 453, 459
 Cerebral 193, 212, 250
 aneurysm 193
 atrophy 250
 dysgenesis 212
 Cerebrospinal 24, 192, 204, 231, 235, 238, 241, 242, 243, 247, 250, 330, 464, 466
 fluid (CSF) 24, 192, 204, 231, 235, 238, 241, 242, 243, 247, 250, 464, 466
 lymphocytosis 330
 Cervical lymphadenopathy 102
 Chest radiographs 49, 123
 Childhood 186, 216, 267, 276, 316
 atopic dermatitis impact scale (CADIS) 276
 eczema 267
 epilepsies 186, 216
 primary angiitis 316
 vasculitis 316
 Children on methotrexate therapy 84
 Children's dermatology life quality index (CDLQI) 276
 Choanal stenosis 8
 Cholangiocarcinoma 438
 Cholestasis 17, 68, 458, 461
 Choreoathetosis 213
 Chromosomal microarray analyses (CMAs) 407
 Chronic 3, 17, 55, 239, 348
 lymphocytic inflammation 239
 neurological diseases 3
 pancreatitis (CP) 17
 peritonitis 348
 persistent synovitis 55
 Churg-Strauss syndrome 316
 Cisplatin monotherapy 445
 CNS 110, 232, 250
 demyelination 232
 ischemia 110
 lymphoma 250
 Colitis, ulcerative 15, 27
 Coma 126, 196, 234
 medical induced 196
 Communicable disease 1, 2, 4, 171
 Comorbidities 2, 206, 260, 272, 276, 341
 mental health 206, 276
 Computed tomography (CT) 102, 110, 193, 194, 195, 217, 219, 439, 444
 Computing technology 408

Conditions mimicking chronic arthritis 45
Conductance regulator (CFTR) 10
Congenital 3, 19, 26, 144, 159, 198, 400
 adrenal hyperplasia (CAH) 19
 anomalies 198, 400
 craniofacial disorders 144
 hyperthyroidism 19
 infections 3
 lymphangioma 159
 obstructing posterior urethral membranes (COPUM) 26
 tooth 144
Conjugate eye movements 191
Conjunctivitis 93, 291
Connective tissue disorders 44, 239
Coronary artery 96, 101, 102, 103, 104, 105, 106
 aneurysms 101, 103, 104, 105, 106
 lesions 96, 102, 104, 105
Cortical dysplasia 198, 206, 216
Corticosteroids 91, 105, 107, 245, 310, 318, 319, 351, 352, 432, 433
Cough 10, 11, 14, 191, 377
COX-deficient Leigh syndrome 458
Cranial nerve disorder 345
Creatine kinase (CK) 441, 452, 460, 465, 466
Creatinine phosphokinase 81
CREST syndrome 52
Crohn's disease (CD) 15
Cryptorchidism 26
CT images 75, 93, 94
Cushing 19, 353
 disease 19
 syndrome 19, 353
Cystic fibrosis 10
Cytokines 57, 118, 126, 175, 274, 288, 290, 313, 336, 355, 357
 anti-inflammatory 57
 inflammatory 288
 pro-inflammatory 175
Cytomegalovirus 121, 234, 328, 331, 377
Cytopenias 127, 128, 327, 354, 388
Cytoskeleton 441

D

Damage 64, 67, 119, 214, 243, 330, 342, 345, 346, 347, 349, 350, 354, 357, 358, 359, 360, 361
 associated molecular pattern (DAMP) 330
 autoimmune 119
 hypoxic 214
 immune-mediated 243
 pediatric 347
 renal 358, 361
Defects of protein-coding genes 457
Deficiency 13, 18, 471
 plasminogen 13
 pyruvate carboxylase 471
 pyruvate dehydrogenase 471
 thyroid hormone 18
Demyelinating 192, 231, 232, 233, 246, 247
 disorders 192, 231, 232, 233
 lesions 246, 247
Dental 138, 147, 148, 149, 160
 injury 147
 lamina cyst 160
 trauma 138, 147, 148, 149, 160
Deoxyribonuclease 331
Depressive disorders 2
Dermatitis 6, 282
Dermatology life quality index (DQLQI) 276, 293
Developmental dislocation of the hip (DDH) 21
Diabetes 3, 17, 18, 27, 71, 152, 153, 172, 177, 178, 187, 246, 275, 294, 349, 456, 457, 461, 463, 464, 465, 476
 gestational 172, 177, 178, 187, 463
 insulin-dependent 275
 mellitus (DM) 18, 71, 153, 178, 246, 456, 457
Diabetic ketoacidosis (DKA) 18
Diarrhea 3, 9, 13, 15, 99, 271, 282, 405, 431, 432, 463
Diencephalic syndrome 247
DiGeorge syndrome 400
Dihydrofolate reductase 353

- Diseases 1, 2, 3, 10, 11, 12, 15, 16, 18, 23, 24, 27, 28, 41, 45, 54, 55, 56, 57, 138, 141, 144, 160, 187, 190, 267, 272, 278, 279, 282, 283, 289, 290, 295, 316, 327, 330, 377, 400, 405, 428, 429, 431, 446
- allergic 267, 272, 279, 295
- autoimmune post-infectious 24
- auto-inflammatory 428, 429, 431
- autosomal recessive 10, 330
- cardiac 11
- celiac 16, 27
- congenital heart 11, 12, 190, 377, 400, 405
- connective tissue 45, 316
- crohn's 15, 27
- dental 138, 144, 160
- diarrheal 1, 2, 3
- gingival 141
- heart 3
- immune deficiency 278
- immunological 16
- inflammatory 141, 289
- inflammatory bowel 15, 45, 55, 56, 57
- inflammatory skin 282, 290
- ischemic cerebrovascular 23
- joint 41, 54
- malignant 282, 283
- metabolic 18, 187
- metastatic tumor 446
- neuropsychiatric 327
- pediatric 2, 3, 28
- rheumatic heart 11
- Disease-modifying 54, 55, 239, 240, 248, 351, 353, 359
- anti-rheumatic drugs (DMARDs) 54, 55, 351, 353, 359
- therapies (DMTs) 239, 240
- therapy 248
- Disorders 13, 77, 186, 220, 221, 222, 223, 236, 243, 289, 333, 345, 453, 456, 457, 458, 460, 463, 464, 466, 475, 476, 477
- antibody-induced 243
- cardiac 463
- cardiovascular 476
- congenital 464
- encephalopathic 458
- immune-mediated 236
- inflammatory 77, 289
- myopathic 458
- neurodegenerative 476
- renal 333, 345, 453, 460
- Disseminated neurodermatitis 260
- DNA 289, 330, 343, 346, 386, 387, 411, 412, 455, 460, 463, 466, 467
- chromosomal 411, 412
- cytosolic 330
- mitochondrial 455, 460, 463, 466
- DNA repair process 390
- Dominant theta activity 212
- Doose syndrome 203, 218
- Dopamine transporters detection 195
- Down's syndrome 152, 214
- Dravet syndrome 186, 196, 197, 199, 214, 222
- Drowsiness 202, 215
- Drug hypersensitivity reactions 103
- Drugs 47, 54, 55, 113, 123, 124, 152, 240, 291, 292, 293, 312, 317, 357, 358, 382, 405, 408, 432, 471
- anti-inflammatory 47, 317, 432
- immunosuppressive 382, 405, 408
- toxicity 123
- Dysarthria 237, 243
- Dysautonomia 465
- Dysfunction 10, 11, 25, 61, 109, 110, 127, 196, 240, 456, 457, 465, 471
- autonomic 11, 196
- cardiac 110
- exocrine pancreas 457
- hepatic 127
- proximal nephron 465
- renal 61, 109
- Dyslipidemia 82, 96, 171, 172
- Dysmorphism 407
- Dysregulation 57, 195, 196, 261, 264, 332, 388, 399, 430, 440
- cytokine 57
- immune 261, 264, 388, 399, 430
- metabolic 195

E

Early 213, 222, 283
 myoclonic encephalopathy (EME) 213, 222
 onset erythroderma 283
 Echocardiography 50, 86, 99, 101, 103, 104,
 110, 466
 Eczema 4, 261, 267, 269, 273, 274, 275, 278,
 279, 283, 295
 molluscum 274, 275
 Eczematous lesions 268, 270, 282, 283
 Edema 25, 102, 155, 235, 280, 281
 epidermal intercellular 280
 Effects 119, 288, 290, 470
 anti-inflammatory 288, 290
 fibrinolytic 119
 synergistic 470
 Ehler-Danlos syndrome 156
 Electrocardiography 106, 334, 466
 Electromyography 81, 466, 467
 Electrophoresis 468
 ELISA technique 52
 Embryogenesis 437, 438
 Embryologic tumors 437, 438, 439
 Encephalitis 3, 23, 155, 186, 192, 194, 206
 epileptic Rasmussen 206
 Encephalomyelitis 231
 Encephalomyopathy 452, 456, 459, 460, 464
 mitochondrial neurogastrointestinal 459
 Encephalopathy 192, 202, 215, 221, 222, 465
 autoimmune 192
 genetic-epileptic 202
 myoclonic 215, 222
 neurodegenerative 221
 progressive 465
 Endocardial cushion defect (ECD) 12
 Endocrine diseases 3
 Endothelial dysfunction 96, 174
 Endothelin receptor antagonists
 Phosphodiesterase 76
 Energy metabolism 453, 454
 essential aerobic 454
 Entesitis-related arthritis (ERA) 49, 53, 55,
 56, 57, 121

Enzyme 19, 394, 409
 dysfunction 19
 replacement therapy (ERT) 394, 409
 Epidermal Langerhans cell 263
 Epidermidis 265, 266
 Epididymitis 26
 Epilepsy 186, 198, 199, 205, 206, 215, 461,
 474
 medial temporal 198
 mitochondrial 461, 474
 neurosurgery 186
 of infancy with migrating focal seizures
 (EIMFS) 198, 199, 215
 surgery 205, 206
 Epilepsy syndromes 186, 196, 202, 204, 207,
 210
 metabolic 204
 Epileptic encephalopathies 196, 202, 210,
 211, 216, 220, 223, 474
 genetic 210, 211
 Epiphyseal dysplasias 45
 Epithelioid sarcoma 442
 Epstein-Barr virus (EBV) 234, 237, 312, 328,
 377
 Erythematous 5, 77, 142, 150, 153, 154, 270,
 282
 candidiasis 153, 154
 erosion 150
 Erythema toxicum neonatorum 7
 Erythrocyte sedimentation rate (ESR) 43, 47,
 48, 60, 64, 103, 104, 114, 127, 343, 432
 Erythroderma 4, 271, 278, 283
 congenital ichthyosiform 283
 Erythromycin 471
 Esophageal disease 51
 Extraocular motility disorders 465
 Eye 53, 122, 460
 abnormalities 460
 disease 53, 122

F

Fabry disease and Leber hereditary 239
 Facial 144, 328, 331

disharmony 144
 dysmorphia 328, 331
 Factors 81, 139, 144, 151, 152, 153, 154, 175, 285, 287, 326, 345, 351, 399, 400, 431, 440, 445, 446
 adverse prognostic 440
 anti-transcriptional intermediary 81
 dietary 139
 immunological 151, 152
 transcription 399, 400
 tumor necrosis 175, 431
 Familial cancer syndromes 439
 Farber's disease 44, 45
 Fasting hypertriglyceridemia 48
 Fatal infantile disorders 458
 Fatty acids 268, 453, 454, 473, 476
 polyunsaturated 268
 Febrile epilepsy seizure syndromes 196
 Fetal 68, 440, 446
 bradycardia 68
 hepatoblastoma 440, 446
 Fever 3, 27, 278
 dengue 3
 hay 27, 278
 Fibrosis, pulmonary 74, 75, 76, 289, 348
 FLAIR images 194
 Flow cytometric methods 406
 Food 141, 152, 281, 288, 289, 290, 291, 295, 312, 313, 355,
 and drug administration (FDA) 281, 288, 289, 290, 291, 355
 complementary 295
 glucose-containing 141
 Foot dermatitis 277
 Frenectomy 151
 Function 205, 206, 232, 236, 240, 243, 244, 248, 262, 273, 331, 342, 350, 378, 384, 390, 394, 399, 411, 452, 458, 475, 477
 antimicrobial peptide 262
 cognitive 236
 impaired left ventricular systolic 475
 impaired neurocognitive 273
 lymphocyte 390
 memory 206
 neurologic 232, 243

 neurological 248
 respiratory 244
 restoring immune 394
 thymic 394, 399
 Function mutations 107
 Fungal infections 4, 361, 375, 377, 381

G

Gardner's syndrome 156, 157
 Gastroesophageal reflux (GER) 14, 75, 457, 463, 471
 Gastrointestinal 3, 10, 13, 14, 312, 354, 453, 460, 463
 bleeding (GIB) 14
 diseases 3
 disorder 463
 infections 312
 symptoms 10, 13, 354, 453, 460, 463
 Gastroschisis 3, 16
 Gene encoding 459
 deoxyguanosine kinase 459
 polymerase 459
 thymidine kinase 459
 Gene therapy (GT) 375, 377, 395, 397, 414, 476, 477
 Genetic 17, 19, 40, 41, 45, 49, 215, 223, 395, 396
 arthropathies 45, 49
 diseases 395
 disorders 17, 19, 40, 41, 215, 223, 396
 Genitourinary 46
 Genitourinary system 25
 Gestational diabetes mellitus 178
 Gingiva 141, 142
 children's 142
 Gingival hyperplasia 289
 Gingivitis 138, 141, 142, 160
 Glatiramer acetate 239, 240
 Glaucoma 121, 123, 124, 125
 Glenohumeral dislocation 20
 Glomerular filtration rate (GFR) 89, 90
 Glomerulonephritis 25, 46, 64, 86, 93, 107, 311, 327, 328

Subject Index

Glomerulopathy 465
Glomerulosclerosis 319
Glucocorticoids 59, 317, 318, 324, 352
 systemic 59
Gluconeogenesis 476
Glucose tolerance disorder 178
Glycoprotein 52, 114
Graft *versus* host disease (GvHD) 377, 379,
 398, 409
Granulomas 15, 388
Granulomatosis 52, 92, 316
 eosinophilic 92, 316
Granulomatous tuberculoid leprosy 395
Grave's disease 18, 19
Guillain-Barré syndrome 244

H

Haemolysis 345
Hand-foot-mouth syndrome 5
Headache disorders 1, 2
Heart failure 11, 93
Helicobacter pylori 312
Hemangioma 138, 159
Hemarthrosis 45
Hematemesis 87
Hematological system 118
Hematologic leukopenia 334
Hematopoietic stem cell transplantation
 (HSCT) 358, 375, 376, 377, 394, 395,
 397, 398, 401, 402, 403, 409, 410, 411,
 412
Hematuria, macroscopic 91, 315
Hemiconvulsion-hemiplegia syndrome 200
Hemispherectomy 206
Hemolytic anemia 25, 63, 118, 327, 333, 334,
 335, 341, 350, 356, 359, 397
 autoimmune 341, 356, 359
 microangiopathic 118
 non-immune microangiopathic 25
Hemolytic uremic syndrome (HUS) 25
Hemophagocytic lymphohistiocytosis 247
Hemophagocytosis 127, 128
Hemorrhagic cystitis 354

Updates on Pediatric Health and Diseases 487

Hemostatic diseases 13
Hepatitis B virus (HBV) 106
Hepatoblastoma 437, 438, 439, 440, 441, 442,
 443, 444, 445, 446, 447
 cholangioblastic 442
 embryonal 439, 440
 mesenchymal 442
Hepatocellular carcinoma 438, 441
Hepatocytes 312, 385, 438
Herpes 5, 121, 153, 154, 275, 357, 377
 infection 154
 keratitis 275
 simplex virus (HSV) 5, 121, 153, 154, 275,
 377
 zoster infection 357
Heteroplasmy 455, 466
Heterozygosis 429
Hirschsprung disease 16
Histiocytosis 251
HIV 3, 44, 250
 Encephalopathy 250
 infection 3, 44
Human 2, 5, 43, 45, 153, 384

 herpesvirus 5
 immunodeficiency virus (HIV) 2, 43, 45,
 153
 papilloma virus (HPV) 384
Hypercortisolism 19
Hyper-IgE syndrome 283
Hyperintense lesion 249
Hypersensitive skin reactions 196
Hypertension 11, 75, 114, 341, 348
 and myocardial inflammation 114
 pulmonary 11, 75, 341, 348
Hypertensive retinopathy 109, 110
Hyperthyroidism 18
Hypertriglyceridemia 128, 173, 178
Hypertrophic cardiomyopathies 457
Hypocomplementemic urticarial vasculitis
 syndrome 331
Hypogammaglobulinemia 355, 356
Hypoglycemia 223, 470
Hypomyelination disorders 232
Hypoparathyroidism 456, 457, 465

- Hypopigmentation 282
 Hypoplastichypomaturation 158
 Hypoproteinemia 315
 Hypothalamic dysfunction 251
 Hypothyroidism 18, 152
 Hypotonia 216, 397, 465
 Hypsarrhythmia 202, 203, 214, 222
- I**
- Idiopathic inflammatory myositis (IIM) 77, 82
 Imaging 107, 210, 211, 246, 445, 466
 cardiac 466
 Immune 13, 119, 261, 262, 263, 264, 341, 356, 359, 379, 397, 398, 411
 deficiency 411
 dysfunction 261, 262, 263, 264
 therapy 119
 thrombocytopenia (ITP) 13, 341, 356, 359, 379, 397, 398
 Immune system 27, 295, 326, 332, 355
 hyperresponsiveness 27
 Immunodeficiency 153, 375, 395, 396, 397, 399, 405
 Immunological reactions 11
 Immunologic thyroid disorder 18
 Immunomodulatory therapy 239
 Immunopathogenesis 357
 Infantile 14, 213, 260, 472
 eczema 260
 epileptic encephalopathies 213
 hypertrophic pyloric stenosis (IHPS) 14
 nephropathy 472
 Infants 398, 401
 athymic 401
 hypotonic 398
 Infections 19, 27, 48, 59, 67, 115, 125, 126, 223, 243, 312, 354, 361, 377, 381, 389, 394
 life-threatening 381
 sinopulmonary 389
 Infectious 54, 112, 232, 282
 aortitis 112
 illnesses 54, 232
 skin diseases 282
 Infective endocarditis 44, 45
 Infiltration 96, 237
 inflammatory 237
 neutrophilic 96
 Inflammation 9, 10, 21, 22, 23, 24, 48, 58, 59, 64, 86, 92, 101, 104, 107, 114, 142, 232, 247, 272, 330, 381
 aggressive tissue 381
 chronic 64, 86, 272
 granulomatous 92, 247
 systemic 59, 330
 Inflammatory 15, 45, 50, 52, 55, 56, 57, 359
 bowel disease (IBD) 15, 45, 55, 56, 57
 myopathies 50, 52, 359
 Inheritance OMIM number 383
 Inhibition 290, 317, 352, 353, 356, 393, 429, 433, 476
 lymphocyte 393
 myeloperoxidase 317
 Injuries 86, 148, 149
 ischemic 86
 traumatic 148, 149
 Immunologic disorder 333
 Inosine monophosphate dehydrogenase 290
 Insufficiency 16, 18, 107, 394
 chronic respiratory 394
 lactase enzyme 16
 renal 107
 thyroid gland 18
 Insulin signaling pathway 476
 Interferonopathies 330, 331
 Interferonopathy 327, 328
 Inter-hemispheric asynchrony 212
 Interstitial lung disease (ILD) 49, 75, 81, 82, 85
 Intraarticular steroids 55
 Iron deficiency 154
 Irritable bowel syndrome (IBS) 15
 Ischemia 86, 107, 109, 114, 125, 232, 473
 mesenteric 109
 Ischemic 109, 110, 193
 infarction 193
 retinopathy 109, 110
 Isolated 250, 316

Subject Index

CNS angiitis 250
cutaneous leucocytoclastic vasculitis 316
Itchy skin 278, 279
condition 278
eruptions 279

J

JAK3 385, 410
deficiency 385, 410
non-receptor tyrosine kinase 385
JAK 291, 358
inhibitors 291
STAT signaling pathway 358
Janz syndrome 202
Japanese encephalitis 234
Junctions 24, 393
costochondral 393
neuromuscular 24
Juvenile 19, 40, 43, 44, 45, 49, 50, 52, 53, 55,
56, 68, 69, 70, 71, 72, 73, 74, 785, 76,
77, 78, 79, 80, 81, 82, 83, 84, 85, 121,
122, 123, 125, 201, 202, 270
ankylosing spondylitis 55
dermatomyositis (JDM) 40, 43, 45, 68, 77,
78, 79, 80, 81, 82, 83, 84, 85
idiopathic arthritis (JIA) 19, 40, 43, 44, 45,
49, 50, 52, 53, 121, 122, 123, 125
localized scleroderma (JLS) 68, 69, 71, 72
myoclonic epilepsy 201, 202
papular dermatosis 270
psoriatic arthritis 53, 56
scleroderma 68
systemic sclerosis (JSSc) 68, 70, 72, 73, 74,
75, 76, 82

K

Kawasaki disease (KD) 13, 46, 50, 86, 95, 96,
97, 98, 99, 100, 101, 102, 104, 105, 106
Kearns-Sayre syndrome (KSS) 456, 461, 464,
466, 474, 475, 476
Keratins 441
acidic 441

Updates on Pediatric Health and Diseases 489

Ketoglutarate dehydrogenase 474
Kidney 25, 26, 89, 340, 350
diseases 25, 89, 350
injury 340
stones 26
Krabbe's disease 250
Kyphosis 22

L

Lactate dehydrogenase 64, 81, 127
Lactic acidosis 452, 456, 457, 458, 461, 462,
464, 468, 469, 472
Lactose 16
intolerance 16
malabsorption 16
Lafora disease 221
Landau-Kleffner 198, 200, 204, 219, 220, 223,
474
aphasia syndrome 198
syndrome (LKS) 198, 200, 204, 219, 220,
223, 474
Langerhans cell histiocytosis and Lymphoma
247
Laryngotracheobronchitis 9
LAT 391
deficiency 391
gene on chromosome 391
Leber's hereditary optic neuropathy (LHON)
453, 457, 460, 461, 465, 466, 472
Legg-Calve-Perthes disease (LCPD) 22
Leg-length discrepancy (LLD) 21
Leigh 452, 456, 458, 461, 462, 466, 467, 472,
475
disorder 467
syndrome 452, 456, 458, 461, 462, 466, 472,
475
Lennox-Gastaut syndrome (LGS) 198, 200,
203, 218, 219, 223
Lesions 7, 67, 70, 71, 77, 79, 96, 107, 109,
138, 149, 150, 154, 156, 159, 160, 198,
234, 237, 239, 249, 251, 265, 268, 282,
338, 452, 467,
asymptomatic 150

atherosclerotic 96
 bilateral deep gray 467
 cystic 156
 erythematous 338
 hemangioma 159
 herpetic 154
 iris 7
 multifocal 234
 oral soft tissue 138, 149, 160
 stenotic 107, 109
 tuberous sclerosis 198
 vasculopathic 79
 Leucocytosis 46, 47, 58, 101, 103
 neutrophilic 58
 Leucopenia 47, 63, 68, 460
 Leukocytoclastic vasculitis 52, 90, 91, 310,
 311, 320, 338
 Leukodystrophies 236, 250
 Leukoencephalopathy 239, 250
 Leukopenia 64, 290, 330, 333, 334, 337, 342,
 346
 Lipid milieu 455, 460
 mitochondrial inner membrane 455
 Lipomatosis 462
 Lithiasic cholecystitis 342
 Liver 17, 47, 118, 127, 196, 239, 379, 394,
 437, 438, 439, 444, 446, 455, 458, 459,
 460, 462, 464, 465, 467, 468, 470
 disease 17, 379
 disorder 465
 dysfunction 127, 196, 462, 470
 enzymes 379
 function test 47, 239, 468
 malignancies 394
 neoplasms 438
 tumor 444
 Lobectomy 446
 Lobe epilepsy 201
 idiopathic photosensitive occipital 201
 Lobular capillary hemangioma 7
 Low-contrast visual acuity (LCVA) 242
 Lupus 52, 65, 79, 114, 187, 324, 326, 327,
 334, 336, 337, 339, 340, 344, 349, 353,
 354, 355, 356, 357, 359, 360, 361
 anticoagulant 52, 114

drug-induced 52
 erythematous 337
 nephritis (LN) 334, 339, 340, 353, 354,
 355, 356, 357, 359, 360
 pathogenesis 327
 severe neuropsychiatric 355
 Lyme disease 149, 242, 250
 Lymphadenopathy 126, 155, 283, 328, 331
 noonan syndrome 328
 Lymphocytes 125, 126, 375, 377, 378, 379,
 386, 387, 397, 398, 401, 403, 414, 429,
 430
 Lymphoma 13, 247, 289, 389, 397, 399
 Lymphopenia 47, 63, 64, 333, 334, 342, 375,
 378, 394, 399, 405
 Lymphopoiesis 386, 390, 403
 Lymphoproliferation 388, 392

M

Macroglossia 159
 Macrophage activation syndrome 19, 40, 44,
 125, 332
 Macular 121, 123, 124, 463
 edema, cystoid 121, 123, 124
 retinal dystrophy 463
 Magnetic resonance 49, 50, 81, 82, 193, 194,
 195, 236, 238, 240, 242, 245, 246, 444,
 462, 467
 imaging (MRI) 49, 50, 81, 82, 193, 194,
 195, 236, 238, 240, 242, 245, 246, 444,
 462
 spectroscopy (MRS) 193, 194, 195, 467
 Malformations 3, 11, 14, 206, 223, 401, 405
 anatomical 206
 congenital 3, 11, 14, 223
 Malignancy transformation 328
 Mass spectrometry methods 393
 Maternally inherited Leigh syndrome (MILS)
 457
 Maxillary incisors 139
 Maxillofacial discrepancy 144
 Measles 3, 5, 103, 234

Subject Index

Meconium aspiration syndrome 10
Medications 64, 84, 171, 180, 197, 211, 212, 215, 216, 287, 340, 346, 347, 351, 460, 469, 471
 antiepileptic 197, 211, 212
 immunosuppressive 64
 mitochondrial toxic 469
 prophylactic 216
 psychotropic 460
Medulloblastoma 250
Mendelian disorders 458
Menstruation 154
Mental health 2, 28, 272, 273
 care 2
 disorders 28, 272, 273
Mesenchymal tissue elements 439
Mesothelioma 441
Metabolic 17, 19, 171, 172, 175, 177, 178, 179, 186, 192, 194, 205, 236, 247, 378, 383, 392, 393, 394, 397, 453, 465, 468, 469
 acidosis 465, 469
 complications 172, 177, 178
 disorders 17, 19, 179, 186, 192, 194, 205, 236, 247, 378, 383, 392
 epilepsy 186, 205
 pathways 378
 poisoning 393, 394, 397
 reactions 453
 responses 171, 175
 stroke 468
Metabolism 19, 202, 290, 452, 453, 454, 462, 473, 476
 aerobic 453
 anaerobic 473
 carbohydrates 19
 mitochondrial 462
 oxidative 452, 454
Metacarpophalangeal 72
 joints 72
Metachromatic leukodystrophy 250
Metaphyseal 377, 399
 chondrodysplasia 377, 399
 dysplasia without hypotrichosis (MDWH) 399

Updates on Pediatric Health and Diseases 491

Metastatic disease 445
Methotrexate therapy 84
Mevalonate kinase deficiency (MKD) 431
Microscopic hematuria 48, 88, 89, 91
Microthrombosis 118, 119
Migraine 23, 465
Migrating Partial Seizures of Infancy (MPSI) 215, 216
Mitochondrial 392, 399, 453, 454, 455, 456, 457, 459, 460, 461, 466, 467, 468, 469, 473, 474, 476
 depletion syndromes (MDS) 453, 455, 459, 460, 466, 467
 dysfunction 455, 468, 474, 476
 encephalomyopathies 454, 457, 460, 461, 473
 enzyme adenylate kinase 392
 neurogastrointestinal encephalopathy 461
 protein synthesis 456
 RNA processing 399
 therapies 469
Mitochondrial DNA 399, 455, 460, 464
 depletion syndromes 455, 460, 464
 replication 399
Mitotic activity 440
Mixed connective tissue disease (MCTD) 50, 52
Molluscum contagiosum virus infections 275
Moloney murine leukaemia virus 412
Monoarthritis 53
Monocytosis 432
Monogenic 324, 327, 329, 332 337, 358, 360
 disorders 332
 lupus 324, 327, 329, 337, 358, 360
Mononeuritis 93
Mononucleosis 431
Morphological variants in atopic dermatitis 270
Motor neuron disorders 23
Mouth breathing, obstructive 146
MR angiography 110, 114
Mucocutaneous disorder 345
Mucosal 87, 312
 secretions 312
 ulcerations 87

- Mucositis 381, 446
 Multifocal epileptiform activity 211
 Multi-focal lesions 250
 Multiorgan dysfunction 125
 Multiple sclerosis (MS) 231, 232, 233, 236, 237, 238, 239, 240, 241, 244, 247, 249, 251, 252
 and neuromyelitis optica spectrum disorder 233
 Multisystem disorder 45, 453, 456, 457, 460
 Muscle 81, 85
 disease 85
 enzymes 81, 85
 Muscle weakness 40, 41, 74, 79, 243, 460, 462, 463, 464
 facial 243
 respiratory 464
 Muscular dystrophy 464
 Musculoskeletal 334, 347
 joint involvement 334
 organ systems 347
 Mutations 211, 214, 219, 266, 330, 375, 376, 395, 397, 399, 438, 441, 453, 455, 457, 458, 459, 462, 463, 464, 467, 476
 beta-catenin 438
 heterozygous missense pathogenic 211
 mitochondrial DNA 467
 nuclear DNA 455
 pathogenic 462
 Myelin 231, 232, 237
 damage 232
 disorders 232
 oligodendrocyte glycoprotein 231
 Myelitis 243, 244, 334
 infectious 244
 Myeloperoxidase 52, 92
 Myocardial 46, 96, 109, 114, 348
 infarction 348
 inflammation 109, 114
 ischemia 46, 96
 Myocarditis 50, 99, 359
 Myoclonic epilepsy 212, 461, 463
 syndrome of 461, 463
 Myoclonus 213, 214, 219, 222, 223, 462, 465
 erratic 213, 222
 Myoepithelial carcinoma 442
 Myoglobinuria 465
 Myopathy 48, 398, 452, 453, 454, 459, 460, 461, 462, 463, 464, 465, 467
 congenital non-progressive global 398
 immune mediated 467
 mitochondrial 453, 454, 460, 461
 Myositis 63, 75, 339, 345, 346
 tendon friction rubs arthritis 75
 Myositis-associated autoantibodies (MAAs) 81
- ## N
- Nailfold capillaroscopy 76, 80
 Narcolepsy 247
 Nasal ulceration 46
 Natural killer (NK) 126, 264, 378
 Nausea 123, 197, 217, 289, 290, 446, 463, 465
 Necrosis 43, 95, 143, 155, 243, 313, 349, 442, 443
 avascular 43, 95, 349
 tooth 155
 Neonatal 1, 2, 3, 205, 211, 294, 375, 393, 400, 402, 403, 472
 diabetes 205
 disorders 1, 2
 emollient therapy 294
 encephalopathy 472
 epileptic encephalopathies (NEE) 211
 hepatitis 393
 hypocalcemia 400
 infections 3
 screening 375, 402
 thymectomy 403
 Neoplasia 219, 387, 390
 Neoplasm 249, 437, 438, 444, 445, 446
 embryologic 438
 Neovascularization 108
 Nephritis 50, 89, 122, 317, 318, 320, 339, 340, 350, 388
 crescentic 320
 tubulointerstitial 122, 340
 Nephroblastoma 26, 438, 440

Subject Index

Nephrolithiasis 26
Nephropathy 65, 310, 315, 318, 340, 458, 464, 472
 antiphospholipid 65, 340
Nephrotoxicity 289, 340, 446
Nervous system 23, 114
 diseases 23
 ischemia 114
Netherton syndrome 283
Neuro-Behcet disease 239
Neuroblastoma 24, 43, 45, 437, 438, 441
Neuroimaging 216, 220, 234, 238, 249, 251, 467, 470
Neurological 23, 213, 223, 225, 250, 345, 390
 deterioration 223
 disorders 213, 225, 390
 problems 23
 regression 250
 disease 345
Neurologic disorder 333
Neurometabolic disorders 23, 214
Neuromyelitis optica spectrum disorders 233, 245
Neuronal ceroid lipofuscinosis (NCLs) 221
Neurons 221, 232, 237, 246
 myelinated 232
Neuropathy 221, 316, 340, 453, 457, 461, 463, 465
 predominant demyelinating 463
 sensory 457
Neuropsychiatric medications ingestion 187
Neurosarcoidosis 239, 247
Neurotransmitters 223, 473
Neutropenia 353, 393, 397, 464
Neutrophilia 127, 432
Neutrophilic leukocytosis 238
Next-generations sequencing (NGS) 407, 466, 467
Nijmegen syndrome 405
Nipple eczema 277
Nonamer-binding domain (NBD) 388
Non-communicating hydrocephalus diagnosis 194
Nonerosive arthritis 333
Nonpurulent conjunctivitis 97

Updates on Pediatric Health and Diseases 493

Non-sedating antihistamines 286
Non-steroidal anti-inflammatory drugs (NSAIDs) 22, 47, 53, 55, 56, 59, 60, 317, 318
Noonan syndrome (NS) 331
NSAID monotherapy 60
Nutritional disorders 3, 242

O

Obesity-related complications 179
Occupational therapy 85
Odontogenesis 147
Ohtahara syndrome 199, 202, 212, 222, 474
Oligoarthritis 47, 51, 53, 54, 56, 121, 123
Oligodendrocytes 232, 237, 246
Omenn syndrome 375, 380, 381, 382, 388, 389, 390, 396, 399, 401, 406
Onycholysis 56
Onychophagia 145
Ophthalmoplegia 250, 463
Optical coherence tomography 121, 241, 242
Oral 144, 150, 152, 159
 dysfunctions 144
 frictional hyperkeratosis 150
 hygiene 152
 lymphangioma 159
 soft tissue hemangiomas 159
Orchitis 46, 89, 91, 316, 319
Organ dysfunction 125, 452, 455, 477
Organic brain syndrome 345
Oropharyngeal burn injuries 150
Osgood-Schlatter disease (OSD) 21
Osmotic demyelination syndrome 251
Osteochondroma 23
Osteomyelitis 19, 42, 349
Osteonecrosis 353
Osteoporosis 272, 349, 353
Oxidoreductase 454
OXPHOS 454, 455
 disorders 455
 pathway 454, 455

P

- Panayiotopoulos syndrome (PS) 217, 218, 456
 Pancreatic 441, 461
 carcinoma 441
 dysfunction 461
 Pancreatitis 17, 342
 Pancytopenia 379, 465
 Paraphimosis 26
 Parkinsonism 459
 Partial DiGeorge syndrome 400, 404
 Patellofemoral pain syndrome (PFPS) 21
 Pathology, renal 63
 Pathways 119, 126, 290, 313, 331, 332, 397, 438
 cytolytic 126
 lectin complement 313
 nucleic acid degradation 331
 pathophysiologic 119
 purine biosynthesis 290
 purine salvage 397
 sensing 332
 Pediatric 9, 41, 41, 195, 231, 240, 444
 epilepsy 195
 multiple sclerosis 231
 oncology 444
 onset multiple sclerosis 240
 rheumatological services 41
 rheumatology services 41
 rhinosinusitis 9
 Peptic ulcer disease 14
 Periodic fever syndromes 126
 Periodontal disease 141
 Periodontitis 138, 141, 142, 143, 160
 Periodontium 142
 Peripheral 23, 24, 93, 232, 250, 348, 453, 460, 462
 nervous system (PNS) 23, 24, 232, 453, 460
 neuropathy 93, 250, 348, 462
 Peripheral blood 128, 291, 355, 357, 378, 379, 401, 403, 467
 eosinophils 291
 lymphocytes 355
 Peroxisome proliferator activated receptor (PPAR) 476
 Perthes disease 43
 Phagocytosis 353
 Phospholipid-dependent clotting assays 115
 Phosphorylated cytoplasmic immunoreceptor 391
 Photoprotection methods 359
 Physician's global assessment (PGA) 343, 345, 354
 Physiotherapy and occupational therapy 85
 Phytohemagglutinin 378, 406
 Pituitary gland 18, 19
 Pleocytosis 235, 242, 243, 245, 252
 Pleural fibrosis 348
 Pneumococcal vaccination 359
 Pneumomediastinum 10
 POLG 464, 465, 466, 471
 associated mitochondrial disorders 466
 disorder 471
 related disorders 464, 465
 Polyangiitis 52, 92, 316
 microscopic 52, 92, 316
 Polyarthrititis 47, 50, 54, 99, 123
 Polymicrogyria 215, 219
 Positron emission tomography (PET) 109, 194, 195, 219
 Posterior urethral valve (PUV) 26
 Post-transplant lymphoproliferative disorder (PTLD) 409
 Potassium ATPase activity 474
 Prenatal anoxic damage 215
 Prepulseless disease 109
 Primary 19, 153, 396, 399, 411, 454
 adrenal insufficiency (PAI) 19
 embryonic thymic defect 399
 genetic mitochondrial disorders 454
 herpetic gingivostomatitis 153
 immune deficiency treatment consortium (PIDTC) 396, 411
 Primary herpes 153
 gingivostomatitis 153
 Problems 139, 160, 407
 neurodevelopmental 407
 orthodontic 139

respiratory 160
Prognosis 6, 9, 147, 149, 199, 200, 201, 210,
217, 218, 240, 242, 319, 320, 433
Progression 56, 68, 71, 72, 91, 141, 240, 272,
340, 431
 chronic kidney disease 340
Progressive 201, 220, 221, 250, 456, 457, 459
 external ophthalmoplegia (PEO) 456, 457,
 459
 multifocal leukoencephalopathy 250
 myoclonic epilepsies (PMEs) 201, 220, 221
Proinflammatory cytokines 57, 264, 287, 293,
357, 429, 430
Protein(s) 115, 329, 330, 331, 356, 328, 340,
381, 387, 388, 389, 391, 395, 399, 441,
453, 454, 455, 456, 459
 chromatin-remodeling 441
 deafness dystonia 459
 fusion 356
 kinases 328, 389, 391
 plasma 115
 transmembrane 331
 urinary 340
Protein tyrosine 391
 kinase 391
 phosphatase 391
Proteinuria 46, 48, 61, 63, 65, 90, 91, 318,
339, 340, 342, 346, 348, 350, 357, 358
 nephrotic-range 318
Prothrombin time (PT) 48
Prothrombotic risk factors 117, 118
Proximal humeral epiphysiolysis 20
Pseudomembranous candidiasis 153, 154
Psoriasis 6, 53, 56, 57, 152, 278, 282, 289,
388
Psychosis 64, 333, 334, 340, 345
Pulmonary 76, 120, 393
 alveolar proteinosis 393
 arterial hypertension 76
 thromboembolism 120
Purine nucleoside phosphorylase (PNP) 397,
402, 406, 407
PUVA therapy 288
Pyloric stenosis 14
Pyruvate dehydrogenase 462, 474

R

Rash 5, 77, 87, 279, 317, 333, 405
 diffuse photosensitive erythematous macular
 77
 itchy 5, 279
 maculopapular lupus 333
 necrotic 317
 palpable purpuric 87
 reddish 5
 skin eczematous 405
 transient urticarial 87
Rasmussen syndrome 200
Raynaud phenomenon 51, 64, 72, 75, 81, 330
Recent thymic emigrants (RTEs) 403
Receptor-associated periodic syndrome 431
Recombination signal sequences (RSSs) 387
Refluxes, gastroesophageal 14, 457, 463, 471
Refractory 205, 470, 356
 epilepsy 205
 hypotension 470
 Rhus syndrome 356
Reiter's syndrome 57
Relapsing dermatitis 277
Renal 3, 25, 48, 63, 74, 89, 90, 95, 113, 123,
126, 127, 310, 315, 320, 340, 348, 361,
442, 457, 466
 activity 340
 disease 3, 63, 89, 90, 95, 310, 340, 348, 361
 failure 74, 113, 126, 127, 315, 320
 function 25, 48, 90
 function tests 48, 123, 466
 hypoperfusion 25
 medullar carcinoma 442
 tubular acidosis 457
Renovascular hypertension 113
Residual recombinase activity 381, 388
Respiratory 3, 187, 377, 408
 diseases 3
 distress syndrome 3
 infections 187
 syncytial virus (RSV) 377, 408
Response 59, 95, 115, 123, 245, 248, 264,
378, 379, 392, 398, 403, 406, 429

abnormal immunologic 95
 immunological 403, 429
 Reticulocytosis 64
 Rhabdoid tumors 442
 Rhabdomyolysis 460, 465
 Rhabdomyosarcoma 440
 Rheumatic fever 11, 43, 187, 190
 Rheumatoid arthropathy 45
 Rheumatological 40, 47, 125
 disorders 40, 47
 emergencies 125
 Rheumatologic disorders 236, 244
 Rheumatology 47, 125, 343, 347, 351, 359
 damage index 347
 pediatric 47, 125, 343, 351, 359
 Rhinoconjunctivitis 286
 Ribonuclease 399
 Ribosomal RNA processing 399
 Risk 54, 66, 67, 68, 95, 96, 123, 146, 173,
 178, 206, 266, 267, 268, 272, 295, 296,
 394
 anesthesia 206
 cardiometabolic disease 178
 predicting young adult cardiovascular 173
 Risk factors 54, 96, 115, 120, 171, 173, 174,
 176, 177, 178, 237, 350
 clustered metabolic syndrome 177
 metabolic 171, 174
 Ritter disease 4
 Role of antitubercular therapy 113

S

Sarcoidosis 122, 242, 251
 Schilder's disease 248, 249, 251, 252
 SCID by homozygous missense mutation 389
 Sclerosis, hippocampal 198, 200, 214, 222
 SCORing atopic dermatitis (SCORAD) 267,
 280, 281, 291, 292, 293
 Segmental glomerulosclerosis 319, 320
 Segmentectomy 446
 Sepsis 377, 392
 fatal neonatal 392
 Signaling pathways 378, 386, 390

Single 194, 219, 266, 407, 456
 deletions of mtDNA 456
 nucleotide polymorphism (SNP) 266, 407
 photon emission computed tomography
 (SPECT) 194, 219
 Sinus thrombosis 340
 Six areas atopic dermatitis (SASSAD) 281
 Sjögren syndrome 50, 51, 67
 Skill-acquisition techniques 294
 Skin 85, 87, 93, 205, 250, 264, 265, 272, 277,
 279, 289, 338, 341, 379, 432
 cancer 289
 disease 272
 hyperpigmentation 250
 lesional 264
 microbiota 265
 rash 85, 87, 93, 205, 279, 338, 432
 test reaction 277
 ulcers 341
 xerotic 379
 Skin barrier 262, 265, 294
 abnormalities and immune dysfunction 262
 dysfunctions 262, 265, 294
 Skin conditions 7, 260, 280, 294, 296
 inflammatory 294
 multifactorial chronic inflammatory 260,
 296
 Skin lesions 69, 71, 79, 310, 330, 331, 337,
 341, 389
 granulomatous 389
 SLE 51, 118, 326
 and prothrombotic risk factors 118
 and Sjögren syndrome 51
 and thyroid disease 326
 Sleep 23, 177, 198, 202, 203, 204, 212, 213,
 216, 217, 218, 219, 222, 223, 240, 273
 disorders 23
 rapid-eye-movement 204
 Slipped 22, 43
 capital femoral epiphysis (SCFE) 22
 upper femoral epiphysis 43
 Sotos syndrome 437, 439
 SPECT scan 195
 Speech disorders 151, 153, 160
 Spinal cord 238, 243, 244, 245

Subject Index

infarction 244
lesions 238, 245
necrosis 243
Spinal muscular atrophy (SMA) 24, 459
Spondyloarthropathy 56
Spondyloenchondrodysplasia 328
Staphylococcal scalded skin syndrome (SSSS)
4
Staphylococcus 4, 265, 312
aureus 4, 265, 312
epidermidis 265
Stem cell transplantation 476
Steroids, oral 66, 107, 204, 248
Stevens-Johnson syndrome (SJS) 7, 103
STING mutations 331
Strauss syndrome 92
Streptococcal infection 11
Streptococcus pyogenes 4
Stress 20, 151, 152, 153, 154, 444, 466
emotional 154
injury 20
physiologic 466
Stroke 23, 46, 109, 110, 113, 114, 116, 349,
453, 462, 469
typical ischemic 462
Subacute necrotizing encephalomyelopathy
461, 462
Succinyl-CoA synthetase ligase 464
Suspect rheumatologic disorders 41
Suspicion of structural disorder 194
Swallowing dysfunction 85
Symptoms 5, 187, 202, 210, 211, 216, 232,
233, 243, 245, 246, 281, 290, 319, 340,
429, 431
genitourinary 290
neurological 211
neuropsychiatric 340
somatosensory 216
Syndrome 23, 25, 63, 75, 76, 81, 89, 153, 154,
157, 174, 199, 200, 201, 202, 205, 206,
214, 315, 318, 320, 439, 456, 457, 459,
460, 462, 464
anti-synthetase 81
deafness-dystonia 459
epileptic 23

Updates on Pediatric Health and Diseases 497

hyperammonemia 205
nephritic 25, 63, 320
nephritic-nephrotic 320
nephrotic 25, 89, 315, 318, 320, 456, 460,
464
neurocutaneous 214
Synovial hemangioma 45
Synovitis 334, 342
Synthesis, total mitochondrial protein 453,
456
Syphilitic aortitis 112
Systemic 45, 118, 119, 125, 243, 289, 344,
346, 350, 361, 393
autoinflammatory syndromes 45
immunomodulatory agents 289
immunosuppression 125
inflammatory response syndrome 118, 119
lupus erythematosus disease activity index
(SLEDAI) 344, 346, 350, 361
metabolic disorder 393
vasculitis syndrome 243
Systems 13, 17, 74, 76, 116, 159, 410, 457
deep venous 116
endocrine 17, 410, 457
hematologic 13
lymphatic 159
pulmonary 74, 76

T

Telangiectasias 51, 67, 328
Temporal lobe sclerosis 198
Temporomandibular disorders 144
Testicular inflammation 89
Tests 41, 50, 116, 123, 191, 225, 239, 245,
247, 406, 465, 466, 469
latex agglutination 50
metabolic 465
mitochondrial DNA 465
parathyroid 466
serological 245, 247
thyroid function 239
Therapeutic targets 293

- Therapy 47, 54, 55, 63, 65, 84, 85, 94, 95,
 104, 105, 107, 108, 123, 124, 128, 153,
 196, 239, 319, 350, 351, 353, 356, 396,
 410
 aggressive 319
 antiepileptic 196
 corticosteroid 153
 immunoglobulin replacement 410
 immunosuppressant 353
 immunosuppressive 63, 65, 84, 85, 128, 239
 steroid 47, 124
 Thrombocytopenia 13, 47, 63, 64, 68, 118,
 330, 333, 334, 337, 340, 341, 342, 345,
 346, 359
 immune 13, 341, 359
 Thrombocytosis 46, 47, 58, 100, 101, 103,
 107, 127
 Thromboembolism 120
 Thrombosis 114, 115, 116, 117, 118, 119,
 120, 125, 341, 342, 349
 Thymic 398, 399, 401, 404
 disorders 399, 404
 epithelial cells (TECs) 398, 399, 401
 Thymidine 459, 463, 464,
 kinase 464
 phosphorylase (TP) 459, 463
 Thymidylate synthase 353
 Thymus 399, 401, 408
 embryogenesis 399
 transplant 401, 408
 Thyroid 3, 18, 326
 diseases 3, 326
 stimulating hormone (TSH) 18
 Thyroiditis 18, 246
 chronic lymphocytic 18
 Tight junction disorder 263
 TINU syndrome 122
 Tissues 17, 52, 141, 149, 193, 221, 438, 441,
 455, 460, 467
 hematopoietic 467
 Tonsillectomy 428, 429, 430, 433
 Tonsillitis 429, 430
 Tonsillotomy 428, 433
 Topical 288
 phosphodiesterase 288
 selective phosphodiesterase 288
 Toxic 7, 103, 333
 epidermal necrolysis 7, 333
 shock syndrome 103
 Transaminases 465, 468
 Transaminitis 68
 Transcription Inhibition 358
 Transepidermal water loss 261
 Transient 10, 317
 parenteral nutrition 317
 tachypnea of the newborn (TTN) 10
 Transmission 6, 232, 400, 455
 nerve impulses 232
 velocity 232
 Transmitted infections 2
 Transverse myelitis (TM) 24, 231, 233, 237,
 239, 242, 243, 245, 246, 247, 348
 Trauma 3, 45, 138, 147, 148, 153, 154, 155,
 244
 alveolar 148
 dental tissue 147
 Traumatic dental injuries 147
 Treatment 58, 59, 67, 84, 90, 104, 105, 119,
 151, 154, 159, 160, 239, 240, 249, 287,
 317, 318, 320, 342, 351, 352, 408
 anti-inflammatory 105
 anti-tuberculosis 408
 corticosteroid 318, 320
 hydroxychloroquine 351
 orthodontic 154
 tRNA 81, 457, 462
 mutations 457, 462
 synthetase 81
 Tuberculosis and human immunodeficiency
 virus 43
 Tumor(s) 175, 357, 358, 431, 437, 441
 necrosis factor (TNF) 175, 357, 358, 431
 pediatric 437
 yolk sac 441
- U**
- Ulcerative colitis (UC) 15, 27, 89

Subject Index

Ulcers 40, 41, 46, 62, 72, 93, 107, 150, 154, 155, 333, 338, 389, 430
 genital 93
 nasal 46, 333
 nasopharyngeal 338
 necrotic 107
Ultrasonography 318
Underlying inflammatory diseases 126
Unverricht-Lundborg disease (ULD) 221, 223
Urethritis 99, 101
Urinary tract infections 3, 27, 187, 312
Urine 63, 64, 66, 89, 99, 334
 creatinine 89
 microscopy 63, 64, 66, 99
 protein 89, 334
Urticaria, chronic 293

V


Valvular disease 348
Varicella zoster virus (VZV) 5, 121, 377
Vascular 71, 110
 imaging by angiography 110
 malformations 71
Vasculitic 114, 245
 disorder 114
 lesions 245
Vasculitis 40, 46, 52, 85, 86, 91, 92, 100, 236, 238, 247, 310, 311, 316, 319, 338, 342, 345
 cerebral 91, 319
 coronary 100
 disorders 247
 urticarial 338, 342
Vasculitis rash 341
Venous 116, 120, 341, 348
 stasis 348
 thrombosis 116, 120, 341, 348
Ventricular 12, 475
 septal defect (VSD) 12
 tachycardia 475
Verbal agnosia 198, 219
Vermillion rim and perioral skin 154
Vesicular rash 155

Updates on Pediatric Health and Diseases 499

Vessel wall histopathology 113
Viral infections, systemic 377
Viruse(s) 5, 9, 275, 377, 412
 gibbon-ape leukaemia 412
 respiratory syncytial 377
 parainfluenza 9, 377
Visual 187, 217, 218, 222, 241
 evoked potentials (VEPs) 218, 241
 hallucinations 187, 217, 222
Vomiting 23, 99, 123, 187, 197, 217, 290, 431, 432, 462, 465
Vulvovaginitis 27

W

WBC-filtered blood products 377
Weber tests 191
Wegener granulomatosis 316
Weston-Hurst disease 235
West syndrome 199, 202, 203, 212, 214, 222, 474
Wet-wrap therapy 286
White syndrome 462
Whole-exome sequencing (WES) 225, 376, 407
Willebrand disease 13
Wiskott-Aldrich syndrome 283, 405
Wnt-beta-catenin 438
 pathway 438
 signaling 438
Wnt signaling pathway 438



Nima Rezaei

Professor Nima Rezaei gained his medical degree (MD) from Tehran University of Medical Sciences and subsequently obtained an MSc in molecular and genetic medicine and a Ph.D. in clinical immunology and human genetics from the University of Sheffield, UK. He also completed a short fellowship in paediatric clinical immunology and bone marrow transplantation at Newcastle General Hospital. He is now the Full Professor of immunology and the Vice Dean of International Affairs, School of Medicine, Tehran University of Medical Sciences, and the co-founder and head of the Research Center for Immunodeficiencies. He is also the founding president of the Universal Scientific Education and Research Network (USERN). He has already been the director of more than 50 research projects and has designed and participated in several international collaborative projects. He is an Editorial Assistant or Board Member for more than 30 international journals. He has edited more than 30 international books, presented more than 500 lectures/posters in congresses/meetings, and published more than 1,000 scientific papers in international journals.



Noosha Samieefar

A seventh-year student of Medical and Master's degree in public health at Shahid Beheshti University of Medical Sciences has a commitment and engagement for volunteering and mentoring. As a medical student, she has volunteered for several scientific and executive positions like managing director and research manager of Network of Interdisciplinarity in Neonates and Infants (NINI), USERN Offices manager, executive director, and research deputy of Shahid Beheshti University of Medical Sciences USERN Office and executive director or committee member of about fifty scientific national and international events. Pediatrics, immunology, and allergy is her field of interest in research and practice.